

# Peter Goadsby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8741590/publications.pdf>

Version: 2024-02-01

865  
papers

78,300  
citations

399

133  
h-index

816

246  
g-index

897  
all docs

897  
docs citations

897  
times ranked

18396  
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33, 629-808.	3.9	6,757
2	Migraine – Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	27.0	1,692
3	Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology, 1990, 28, 183-187.	5.3	1,386
4	Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews, 2017, 97, 553-622.	28.8	1,168
5	Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. New England Journal of Medicine, 2004, 350, 1104-1110.	27.0	1,118
6	Hypothalamic activation in cluster headache attacks. Lancet, The, 1998, 352, 275-278.	13.7	1,092
7	The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology, 1993, 33, 48-56.	5.3	1,021
8	Oral triptans (serotonin 5-HT <sub>1B/1D</sub> agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, The, 2001, 358, 1668-1675.	13.7	927
9	New Appendix Criteria Open for a Broader Concept of Chronic Migraine. Cephalalgia, 2006, 26, 742-746.	3.9	846
10	Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology, 1988, 23, 193-196.	5.3	814
11	A review of paroxysmal hemicranias, SUNCT syndrome and other short- lasting headaches with autonomic feature, including new cases. Brain, 1997, 120, 193-209.	7.6	662
12	A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine, 2017, 377, 2123-2132.	27.0	661
13	EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. European Journal of Neurology, 2009, 16, 968-981.	3.3	649
14	A Report on the Journal 2004. Cephalalgia, 2004, 24, 1-1.	3.9	639
15	Human in vivo evidence for trigeminovascular activation in cluster headache Neuropeptide changes and effects of acute attacks therapies. Brain, 1994, 117, 427-434.	7.6	621
16	Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. Cephalalgia, 2000, 20, 765-786.	3.9	615
17	Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine, 2017, 377, 2113-2122.	27.0	573
18	Premonitory symptoms in migraine. Neurology, 2003, 60, 935-940.	1.1	572

#	ARTICLE	IF	CITATIONS
19	Brainstem activation specific to migraine headache. <i>Lancet, The</i> , 2001, 357, 1016-1017.	13.7	564
20	Triptans (Serotonin, 5-HT <sub>1B/1D</sub> Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials. <i>Cephalalgia</i> , 2002, 22, 633-658.	3.9	554
21	Correlation between structural and functional changes in brain in an idiopathic headache syndrome. <i>Nature Medicine</i> , 1999, 5, 836-838.	30.7	533
22	Cluster headache. <i>Neurology</i> , 2002, 58, 354-361.	1.1	525
23	The Trigeminovascular System in Humans: Pathophysiologic Implications for Primary Headache Syndromes of the Neural Influences on the Cerebral Circulation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 115-127.	4.3	521
24	The International Classification of Headache Disorders: 2nd edition. <i>Lancet Neurology, The</i> , 2003, 2, 720.	10.2	496
25	Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Cephalalgia</i> , 2007, 27, 814-823.	3.9	496
26	Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). <i>Cephalalgia</i> , 2011, 31, 301-315.	3.9	467
27	Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. <i>Brain</i> , 2004, 127, 220-230.	7.6	457
28	Diencephalic and brainstem mechanisms in migraine. <i>Nature Reviews Neuroscience</i> , 2011, 12, 570-584.	10.2	454
29	CGRP and its receptors provide new insights into migraine pathophysiology. <i>Nature Reviews Neurology</i> , 2010, 6, 573-582.	10.1	418
30	The International Classification of Headache Disorders, 2nd Edition (ICHD-II) – Revision of Criteria for 8.2 Medication-Overuse Headache. <i>Cephalalgia</i> , 2005, 25, 460-465.	3.9	417
31	Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. <i>Lancet Neurology, The</i> , 2002, 1, 251-257.	10.2	416
32	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. <i>Lancet Neurology, The</i> , 2010, 9, 373-380.	10.2	413
33	A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. <i>Brain</i> , 2005, 128, 932-939.	7.6	404
34	Galcanezumab in chronic migraine. <i>Neurology</i> , 2018, 91, e2211-e2221.	1.1	399
35	A Positron Emission Tomographic Study in Spontaneous Migraine. <i>Archives of Neurology</i> , 2005, 62, 1270.	4.5	395
36	EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalgias. <i>European Journal of Neurology</i> , 2006, 13, 1066-1077.	3.3	388

#	ARTICLE	IF	CITATIONS
37	Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. <i>Brain</i> , 2002, 125, 1496-1509.	7.6	384
38	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1999.	7.4	379
39	Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. <i>Brain</i> , 2014, 137, 232-241.	7.6	378
40	Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. <i>Cephalalgia</i> , 2011, 31, 271-285.	3.9	358
41	Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. <i>Brain</i> , 2003, 126, 1801-1813.	7.6	355
42	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. <i>Lancet, The</i> , 2018, 392, 2280-2287.	13.7	348
43	Functional magnetic resonance imaging in spontaneous attacks of SUNCT: Short-lasting neuralgiform headache with conjunctival injection and tearing. <i>Annals of Neurology</i> , 1999, 46, 791-794.	5.3	338
44	Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. <i>Lancet, The</i> , 2007, 369, 1099-1106.	13.7	337
45	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology, The</i> , 2014, 13, 1100-1107.	10.2	333
46	Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Neurology, The</i> , 2014, 13, 885-892.	10.2	332
47	Ergotamine in the acute treatment of migraine: A review and European consensus. <i>Brain</i> , 2000, 123, 9-18.	7.6	329
48	PET and MRA findings in cluster headache and MRA in experimental pain. <i>Neurology</i> , 2000, 55, 1328-1335.	1.1	327
49	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT <sub>1B/1D</sub> Agonists) in the Acute Treatment of Migraine. <i>Headache</i> , 2004, 44, 414-425.	3.9	327
50	Greater occipital nerve injection in primary headache syndromes – prolonged effects from a single injection. <i>Pain</i> , 2006, 122, 126-129.	4.2	321
51	Neurobiology of migraine. <i>Neuroscience</i> , 2009, 161, 327-341.	2.3	318
52	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016, 15, 382-390.	10.2	312
53	The clinical characteristics of headache in patients with pituitary tumours. <i>Brain</i> , 2005, 128, 1921-1930.	7.6	279
54	High-Flow Oxygen for Treatment of Cluster Headache. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2451.	7.4	278

#	ARTICLE	IF	CITATIONS
55	Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)--a prospective clinical study of SUNCT and SUNA. <i>Brain</i> , 2006, 129, 2746-2760.	7.6	277
56	Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. <i>British Journal of Pharmacology</i> , 2004, 142, 1171-1181.	5.4	274
57	Does Chronic Daily Headache Arise De Novo in Association With Regular Use of Analgesics?. <i>Headache</i> , 2003, 43, 179-190.	3.9	257
58	Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. <i>Pain</i> , 2004, 109, 367-378.	4.2	253
59	Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. <i>Cephalalgia</i> , 2011, 31, 712-722.	3.9	251
60	Recent advances in understanding migraine mechanisms, molecules and therapeutics. <i>Trends in Molecular Medicine</i> , 2007, 13, 39-44.	6.7	250
61	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). <i>Journal of Headache and Pain</i> , 2012, 13, 361-378.	6.0	248
62	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	3.9	245
63	The trigeminocervical complex and migraine: Current concepts and synthesis. <i>Current Pain and Headache Reports</i> , 2003, 7, 371-376.	2.9	244
64	Posterior Hypothalamic and Brainstem Activation in Hemicrania Continua. <i>Headache</i> , 2004, 44, 747-761.	3.9	244
65	BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. <i>Cephalalgia</i> , 2014, 34, 114-125.	3.9	241
66	Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. <i>Brain Research</i> , 1993, 629, 95-102.	2.2	239
67	Migraine: Preventive Treatment. <i>Cephalalgia</i> , 2002, 22, 491-512.	3.9	237
68	Migraine in pregnancy. <i>BMJ: British Medical Journal</i> , 2008, 336, 1502-1504.	2.3	237
69	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 737-745.	13.7	236
70	Efficacy and safety of eptinezumab in patients with chronic migraine. <i>Neurology</i> , 2020, 94, e1365-e1377.	1.1	236
71	Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. <i>Neurology</i> , 2014, 83, 958-966.	1.1	235
72	Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. <i>New England Journal of Medicine</i> , 2019, 381, 142-149.	27.0	235

#	ARTICLE	IF	CITATIONS
73	The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?. <i>Neuroscience</i> , 2001, 106, 793-800.	2.3	231
74	The pharmacology of headache. <i>Progress in Neurobiology</i> , 2000, 62, 509-525.	5.7	228
75	Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. <i>Neurology</i> , 2009, 72, 341-345.	1.1	225
76	The distribution of trigeminovascular afferents in the nonhuman primate brain <i>Macaca nemestrina</i> : a c-fos immunocytochemical study. <i>Journal of Anatomy</i> , 1997, 190, 367-375.	1.5	214
77	Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. <i>Neuropeptides</i> , 1990, 16, 69-75.	2.2	213
78	Obesity, migraine, and chronic migraine. <i>Neurology</i> , 2007, 68, 1851-1861.	1.1	210
79	Hypnic headache. <i>Neurology</i> , 2003, 60, 905-909.	1.1	207
80	Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS). <i>Headache</i> , 2011, 51, 1058-1077.	3.9	204
81	Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. <i>British Journal of Pharmacology</i> , 1993, 109, 788-792.	5.4	203
82	Current practice and future directions in the prevention and acute management of migraine. <i>Lancet Neurology</i> , The, 2010, 9, 285-298.	10.2	203
83	Chronic migraine headache prevention with noninvasive vagus nerve stimulation. <i>Neurology</i> , 2016, 87, 529-538.	1.1	191
84	Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <i>Brain</i> , 2019, 142, 1894-1904.	7.6	191
85	Posterior hypothalamic activation in paroxysmal hemicrania. <i>Annals of Neurology</i> , 2006, 59, 535-545.	5.3	190
86	Eletriptan in acute migraine. <i>Neurology</i> , 2000, 54, 156-156.	1.1	187
87	Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials. <i>Cephalalgia</i> , 2006, 26, 1168-1170.	3.9	185
88	Brainstem Influences on the Cephalic Circulation: Experimental Data From Cat and Monkey of Relevance to the Mechanism of Migraine. <i>Headache</i> , 1983, 23, 258-265.	3.9	182
89	Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. <i>Cephalalgia</i> , 2014, 34, 986-993.	3.9	178
90	Trial of Galcanezumab in Prevention of Episodic Cluster Headache. <i>New England Journal of Medicine</i> , 2019, 381, 132-141.	27.0	178

#	ARTICLE	IF	CITATIONS
91	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 51-60.	13.7	178
92	Activation of 5-HT <sub>1B/1D</sub> receptor in the periaqueductal gray inhibits nociception. <i>Annals of Neurology</i> , 2004, 56, 371-381.	5.3	175
93	Glyceryl trinitrate triggers premonitory symptoms in migraineurs. <i>Pain</i> , 2004, 110, 675-680.	4.2	174
94	Cluster Headache. <i>Cephalalgia</i> , 2000, 20, 787-803.	3.9	173
95	“Visual snow”™ a disorder distinct from persistent migraine aura. <i>Brain</i> , 2014, 137, 1419-1428.	7.6	173
96	Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)-1 D Receptor Agonist 311C90. <i>Headache</i> , 1994, 34, 394-399.	3.9	170
97	Neuropeptides in Migraine and Cluster Headache. <i>Cephalalgia</i> , 1994, 14, 320-327.	3.9	169
98	Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?. <i>Pain</i> , 1996, 67, 355-359.	4.2	168
99	Intranasal sumatriptan in cluster headache. <i>Neurology</i> , 2003, 60, 630-633.	1.1	168
100	Early vs. Non-Early Intervention in Acute Migraine “Act When Mild (AwM)™. A Double-Blind, Placebo-Controlled Trial of Almotriptan. <i>Cephalalgia</i> , 2008, 28, 383-391.	3.9	168
101	The Hypothalamic Orexinergic System: Pain and Primary Headaches. <i>Headache</i> , 2007, 47, 951-962.	3.9	167
102	Deep Brain Stimulation for Intractable Chronic Cluster Headache: Proposals for Patient Selection. <i>Cephalalgia</i> , 2004, 24, 934-937.	3.9	166
103	STIMULATION OF THE SUPERIOR SAGITTAL SINUS INCREASES METABOLIC ACTIVITY AND BLOOD FLOW IN CERTAIN REGIONS OF THE BRAINSTEM AND UPPER CERVICAL SPINAL CORD OF THE CAT. <i>Brain</i> , 1991, 114, 1001-1011.	7.6	164
104	Neural Processing of Craniovascular Pain: A Synthesis of the Central Structures Involved in Migraine. <i>Headache</i> , 1991, 31, 365-371.	3.9	163
105	Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. <i>Brain</i> , 1996, 119, 249-256.	7.6	162
106	Persistence of attacks of cluster headache after trigeminal nerve root section. <i>Brain</i> , 2002, 125, 976-984.	7.6	162
107	P/Q-Type Calcium-Channel Blockade in the Periaqueductal Gray Facilitates Trigeminal Nociception: A Functional Genetic Link for Migraine?. <i>Journal of Neuroscience</i> , 2002, 22, RC213-RC213.	3.6	161
108	Gray matter changes related to chronic posttraumatic headache. <i>Neurology</i> , 2009, 73, 978-983.	1.1	161

#	ARTICLE	IF	CITATIONS
109	Calcitonin gene-related peptide and pain: a systematic review. <i>Journal of Headache and Pain</i> , 2017, 18, 34.	6.0	161
110	Paroxysmal hemicrania: a prospective clinical study of 31 cases. <i>Brain</i> , 2008, 131, 1142-1155.	7.6	160
111	Oral zolmitriptan is effective in the acute treatment of cluster headache. <i>Neurology</i> , 2000, 54, 1832-1839.	1.1	159
112	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710.	3.9	154
113	Migraine. <i>Nature Reviews Disease Primers</i> , 2022, 8, 2.	30.5	154
114	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. <i>Cephalalgia</i> , 2018, 38, 959-969.	3.9	153
115	Neurovascular Headache and A Midbrain Vascular Malformation: Evidence for A Role of the Brainstem in Chronic Migraine. <i>Cephalalgia</i> , 2002, 22, 107-111.	3.9	152
116	EFNS guideline on the drug treatment of migraine – report of an EFNS task force. <i>European Journal of Neurology</i> , 2006, 13, 560-572.	3.3	152
117	Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study. <i>Lancet Neurology</i> , The, 2008, 7, 1001-1012.	10.2	151
118	The vascular theory of migraine – a great story wrecked by the facts. <i>Brain</i> , 2009, 132, 6-7.	7.6	151
119	Nitric oxide synthesis couples cerebral blood flow and metabolism. <i>Brain Research</i> , 1992, 595, 167-170.	2.2	149
120	Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. <i>Pain</i> , 1997, 73, 23-28.	4.2	149
121	Hemicrania continua: a clinical study of 39 patients with diagnostic implications. <i>Brain</i> , 2010, 133, 1973-1986.	7.6	148
122	Decreased carotid arterial resistance in cats in response to trigeminal stimulation. <i>Journal of Neurosurgery</i> , 1984, 61, 307-315.	1.6	147
123	Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. <i>Headache</i> , 2016, 56, 306-322.	3.9	147
124	Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention. <i>JAMA Neurology</i> , 2018, 75, 187.	9.0	147
125	Medication-overuse headache in patients with cluster headache. <i>Neurology</i> , 2006, 67, 109-113.	1.1	146
126	Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. <i>British Journal of Pharmacology</i> , 2002, 137, 62-68.	5.4	145



#	ARTICLE	IF	CITATIONS
127	New therapeutic approaches for the prevention and treatment of migraine. <i>Lancet Neurology</i> , The, 2015, 14, 1010-1022.	10.2	144
128	The Mode of Action of Sumatriptan is Vascular? A Debate. <i>Cephalalgia</i> , 1994, 14, 401-410.	3.9	143
129	Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. <i>Developmental Medicine and Child Neurology</i> , 2002, 44, 490-493.	2.1	142
130	Neuropeptide Changes in a case of Chronic Paroxysmal Hemicrania—Evidence for Trigemino-Parasympathetic Activation. <i>Cephalalgia</i> , 1996, 16, 448-450.	3.9	141
131	Effectiveness of Intranasal Zolmitriptan in Acute Cluster Headache. <i>Archives of Neurology</i> , 2006, 63, 1537.	4.5	141
132	Migraine: disease characterisation, biomarkers, and precision medicine. <i>Lancet</i> , The, 2021, 397, 1496-1504.	13.7	141
133	Migraine, aura, and cortical spreading depression: Why are we still talking about it?. <i>Annals of Neurology</i> , 2001, 49, 4-6.	5.3	139
134	A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. <i>Brain</i> , 2004, 127, 1200-1209.	7.6	139
135	Migraine Pathophysiology. <i>Headache</i> , 2005, 45, S14-24.	3.9	139
136	Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 727-737.	10.2	137
137	Pituitary Volume and Headache. <i>Archives of Neurology</i> , 2004, 61, 721.	4.5	136
138	Subcutaneous octreotide in cluster headache: Randomized placebo-controlled double-blind crossover study. <i>Annals of Neurology</i> , 2004, 56, 488-494.	5.3	136
139	Dopamine and Migraine: Biology and Clinical Implications. <i>Cephalalgia</i> , 2007, 27, 1308-1314.	3.9	136
140	Localization of 3 H <sup>3</sup> -Dihydroergotamine binding sites in the cat central nervous system: Relevance to migraine. <i>Annals of Neurology</i> , 1991, 29, 91-94.	5.3	135
141	The migraine postdrome. <i>Neurology</i> , 2016, 87, 309-313.	1.1	134
142	Familial typical migraine. <i>Neurology</i> , 1998, 50, 1428-1432.	1.1	132
143	Chronic migraine—classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171.	10.1	130
144	The Relation Between Migraine, Typical Migraine Aura and “Visual Snow” Headache, 2014, 54, 957-966.	3.9	130

#	ARTICLE	IF	CITATIONS
145	Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. <i>NeuroReport</i> , 2005, 16, 1383-1387.	1.2	129
146	Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse. <i>Cephalalgia</i> , 2009, 29, 1021-1027.	3.9	128
147	Diagnostic delays and mis-management in cluster headache. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 175-179.	2.1	127
148	Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. <i>Brain Research</i> , 1982, 249, 247-254.	2.2	126
149	Management of Trigeminal Autonomic Cephalgias and Hemicrania Continua. <i>Drugs</i> , 2003, 63, 1637-1677.	10.9	126
150	Atogepant for the Preventive Treatment of Migraine. <i>New England Journal of Medicine</i> , 2021, 385, 695-706.	27.0	126
151	Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?. <i>Brain</i> , 2004, 128, 86-97.	7.6	125
152	A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. <i>Neurology</i> , 2013, 80, 642-647.	1.1	125
153	Oral sumatriptan in acute migraine. <i>Lancet, The</i> , 1991, 338, 782-783.	13.7	124
154	Pituitary adenylate cyclase activating polypeptide and migraine. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 1036-1040.	3.7	124
155	Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigemino-vascular Nociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 56-63.	2.5	123
156	Pathophysiology of Migraine. <i>Neurologic Clinics</i> , 2009, 27, 335-360.	1.8	123
157	Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. <i>Journal of Anatomy</i> , 1999, 194, 579-588.	1.5	122
158	Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigemino-vascular Nociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1380-1385.	2.5	122
159	Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society. <i>Headache</i> , 2008, 48, 778-782.	3.9	122
160	Oxygen Inhibits Neuronal Activation in the Trigemino-cervical Complex After Stimulation of Trigeminal Autonomic Reflex, But Not During Direct Dural Activation of Trigeminal Afferents. <i>Headache</i> , 2009, 49, 1131-1143.	3.9	122
161	Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. <i>Neurology</i> , 2015, 84, 1249-1253.	1.1	120
162	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.1	120

#	ARTICLE	IF	CITATIONS
163	Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. <i>European Journal of Neuroscience</i> , 2006, 24, 2825-2833.	2.6	119
164	Diagnostic Criteria for Headache Due to Spontaneous Intracranial Hypotension: A Perspective. <i>Headache</i> , 2011, 51, 1442-1444.	3.9	119
165	Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?. <i>Current Treatment Options in Neurology</i> , 2017, 19, 27.	1.8	119
166	Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. <i>Brain</i> , 1997, 120, 2171-2177.	7.6	118
167	Trigeminovascular nociceptive transmission involves N-methyl-d-aspartate and non-N-methyl-d-aspartate glutamate receptors. <i>Neuroscience</i> , 1999, 90, 1371-1376.	2.3	117
168	Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. <i>Neurology</i> , 2007, 69, 668-675.	1.1	116
169	Cluster headache. <i>BMJ, The</i> , 2012, 344, e2407-e2407.	6.0	116
170	PACAP, a VIP-like Peptide: Immunohistochemical Localization and Effect upon Cat Pial Arteries and Cerebral Blood Flow. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 291-297.	4.3	115
171	Unilateral Photophobia or Phonophobia in Migraine Compared With Trigeminal Autonomic Cephalalgias. <i>Cephalalgia</i> , 2008, 28, 626-630.	3.9	115
172	Biological insights from the premonitory symptoms of migraine. <i>Nature Reviews Neurology</i> , 2018, 14, 699-710.	10.1	115
173	Intravenous dihydroergotamine for inpatient management of refractory primary headaches. <i>Neurology</i> , 2011, 77, 1827-1832.	1.1	114
174	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). <i>Cephalalgia</i> , 2018, 38, 1038-1048.	3.9	113
175	Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. <i>British Journal of Pharmacology</i> , 2004, 142, 1354-1360.	5.4	112
176	Pathophysiology of migraine. <i>Annals of Indian Academy of Neurology</i> , 2012, 15, 15.	0.5	112
177	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. <i>European Journal of Neurology</i> , 2021, 28, 1716-1725.	3.3	112
178	Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. <i>Brain</i> , 1996, 119, 1419-1428.	7.6	111
179	Animal models of migraine: looking at the component parts of a complex disorder. <i>European Journal of Neuroscience</i> , 2006, 24, 1517-1534.	2.6	110
180	Neuronal PAC <sub>1</sub> receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. <i>Science Translational Medicine</i> , 2015, 7, 308ra157.	12.4	109

#	ARTICLE	IF	CITATIONS
181	Magnetic Resonance Angiography in Facial and other Pain: Neurovascular Mechanisms of Trigeminal Sensation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1171-1176.	4.3	108
182	Extracranial vasodilatation mediated by vasoactive intestinal polypeptide (VIP). <i>Brain Research</i> , 1985, 329, 285-288.	2.2	107
183	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019, 39, 1075-1085.	3.9	107
184	Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT <sub>1B/1D</sub> ) receptors. <i>British Journal of Pharmacology</i> , 1997, 122, 918-922.	5.4	106
185	An update on migraine: current understanding and future directions. <i>Journal of Neurology</i> , 2017, 264, 2031-2039.	3.6	106
186	Neurons of the Dopaminergic/Calcitonin Gene-Related Peptide A11 Cell Group Modulate Neuronal Firing in the Trigemino-cervical Complex: An Electrophysiological and Immunohistochemical Study. <i>Journal of Neuroscience</i> , 2009, 29, 12532-12541.	3.6	105
187	Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. <i>Brain</i> , 2016, 139, 2002-2014.	7.6	105
188	Clinical features of migraine aura: Results from a prospective diary-aided study. <i>Cephalalgia</i> , 2017, 37, 979-989.	3.9	105
189	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	3.9	105
190	Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: Cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. <i>Journal of the Autonomic Nervous System</i> , 1998, 70, 15-22.	1.9	104
191	Pathophysiology of Migraine. <i>Neurologic Clinics</i> , 2019, 37, 651-671.	1.8	104
192	No change in the structure of the brain in migraine: a voxel-based morphometric study. <i>European Journal of Neurology</i> , 2003, 10, 53-57.	3.3	102
193	Dopamine: what's new in migraine?. <i>Current Opinion in Neurology</i> , 2010, 23, 275-281.	3.6	102
194	Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. <i>Journal of Headache and Pain</i> , 2015, 16, 535.	6.0	102
195	Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. <i>Current Pain and Headache Reports</i> , 2003, 7, 308-318.	2.9	101
196	Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping. <i>Brain</i> , 2012, 135, 2536-2545.	7.6	101
197	Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. <i>Neurobiology of Disease</i> , 2004, 16, 500-505.	4.4	100
198	Why headache treatment fails. <i>Neurology</i> , 2003, 60, 1064-1070.	1.1	99

#	ARTICLE	IF	CITATIONS
199	SUNCT Syndrome Responsive to Intravenous Lidocaine. <i>Cephalalgia</i> , 2004, 24, 985-992.	3.9	99
200	Modulation of nociceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. <i>Brain</i> , 2010, 133, 2540-2548.	7.6	99
201	Ophthalmoplegic "Migraine" or Recurrent Ophthalmoplegic Cranial Neuropathy. <i>Journal of Child Neurology</i> , 2012, 27, 759-766.	1.4	99
202	Neuropeptides in the Cerebral Circulation: Relevance to Headache. <i>Cephalalgia</i> , 1995, 15, 272-276.	3.9	97
203	Prolactinomas, dopamine agonists and headache: two case reports. <i>European Journal of Neurology</i> , 2003, 10, 169-173.	3.3	97
204	European headache federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015, 17, 5.	6.0	97
205	Long-term safety, tolerability, and efficacy of fremanezumab in migraine. <i>Neurology</i> , 2020, 95, e2487-e2499.	1.1	97
206	Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 64-71.	2.5	96
207	Acid-sensing ion channel 1: A novel therapeutic target for migraine with aura. <i>Annals of Neurology</i> , 2012, 72, 559-563.	5.3	95
208	Behavioral management of the triggers of recurrent headache: A randomized controlled trial. <i>Behaviour Research and Therapy</i> , 2014, 61, 1-11.	3.1	95
209	SUNCT Syndrome or Trigeminal Neuralgia with Lacrimation. <i>Cephalalgia</i> , 2001, 21, 82-83.	3.9	93
210	Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. <i>Neuroscience</i> , 2003, 122, 491-498.	2.3	93
211	Activation of the Trigeminovascular System by Mechanical Distension of the Superior Sagittal Sinus in The Cat. <i>Cephalalgia</i> , 1992, 12, 133-136.	3.9	92
212	Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by l-NAME. <i>Neuroscience Letters</i> , 1999, 266, 173-176.	2.1	92
213	Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. <i>Brain</i> , 2002, 125, 1392-1401.	7.6	92
214	Topiramate Inhibits Trigeminovascular Neurons in the Cat. <i>Cephalalgia</i> , 2004, 24, 1049-1056.	3.9	92
215	A triptan too far?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64, 143-147.	1.9	91
216	Migraine pathogenesis and state of pharmacological treatment options. <i>BMC Medicine</i> , 2009, 7, 71.	5.5	91

#	ARTICLE	IF	CITATIONS
217	Endocannabinoids in the Brainstem Modulate Dural Trigemino-vascular Nociceptive Traffic via CB <sub>1</sub> and 5-HT <sub>1B</sub> Receptors: Implications in Migraine. <i>Journal of Neuroscience</i> , 2013, 33, 14869-14877.	3.6	91
218	Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. <i>Cephalalgia</i> , 2020, 40, 935-948.	3.9	91
219	Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. <i>Neurology</i> , 2001, 56, 273-275.	1.1	90
220	Substance P receptor antagonists in the therapy of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 673-678.	4.1	90
221	Use of sumatriptan in post-ictal migraine headache. <i>Neurology</i> , 1996, 47, 1104-1104.	1.1	88
222	Fos expression in the midbrain periaqueductal grey after trigemino-vascular stimulation. <i>Journal of Anatomy</i> , 2001, 198, 29-35.	1.5	88
223	Diffusion- and Perfusion-Weighted MR Imaging in Persistent Migrainous visual Disturbances. <i>Cephalalgia</i> , 2005, 25, 323-332.	3.9	87
224	Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. <i>Cephalalgia</i> , 2014, 34, 258-267.	3.9	87
225	Dopamine inhibits trigemino-vascular transmission in the rat. <i>Annals of Neurology</i> , 2007, 61, 251-262.	5.3	86
226	Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of the Cortical Spreading Depression Inhibiting Agent Tonabersat in Migraine Prophylaxis. <i>Cephalalgia</i> , 2009, 29, 742-750.	3.9	86
227	Serotonin receptors modulate trigemino-vascular responses in ventroposteromedial nucleus of thalamus: A migraine target?. <i>Neurobiology of Disease</i> , 2006, 23, 491-501.	4.4	85
228	Trigeminal Autonomic Cephalalgias: Paroxysmal Hemicrania, SUNCT/SUNA, and Hemicrania Continua. <i>Seminars in Neurology</i> , 2010, 30, 186-191.	1.4	85
229	Migraine headache is present in the aura phase. <i>Neurology</i> , 2012, 79, 2044-2049.	1.1	85
230	CURRENT CONCEPTS OF THE PATHOPHYSIOLOGY OF MIGRAINE. <i>Neurologic Clinics</i> , 1997, 15, 27-42.	1.8	84
231	Neuropeptides in headache. <i>European Journal of Neurology</i> , 1998, 5, 329-341.	3.3	84
232	TEV-48125 for the preventive treatment of chronic migraine. <i>Neurology</i> , 2016, 87, 41-48.	1.1	84
233	Anti-Migraine Compounds Fail to Modulate the Propagation of Cortical Spreading Depression in the Cat. <i>European Neurology</i> , 1994, 34, 30-35.	1.4	83
234	Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. <i>Brain Research</i> , 1996, 707, 110-118.	2.2	83

#	ARTICLE	IF	CITATIONS
235	Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. <i>Neurology</i> , 2013, 81, 431-436.	1.1	83
236	Direct Evidence for Central Sites of Action of Zolmitriptan (311C90). <i>Cephalalgia</i> , 1997, 17, 153-158.	3.9	82
237	Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. <i>British Journal of Pharmacology</i> , 2003, 140, 558-566.	5.4	82
238	A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. <i>Brain</i> , 2012, 135, 3664-3675.	7.6	82
239	Intravenous Acetylsalicylic Acid Inhibits Central Trigeminal Neurons in the Dorsal Horn of the Upper Cervical Spinal Cord in the Cat. <i>Headache</i> , 1993, 33, 541-544.	3.9	81
240	Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. <i>British Journal of Pharmacology</i> , 2003, 140, 718-724.	5.4	81
241	Clinical features of headache at altitude. <i>Neurology</i> , 2003, 60, 1167-1171.	1.1	81
242	Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. <i>Developmental Medicine and Child Neurology</i> , 2002, 44, 490-3.	2.1	80
243	Cluster headache, hypothalamus, and orexin. <i>Current Pain and Headache Reports</i> , 2009, 13, 147-154.	2.9	80
244	Visual snow syndrome. <i>Neurology</i> , 2020, 94, e564-e574.	1.1	80
245	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019, 39, 1455-1464.	3.9	79
246	Sumatriptan Reverses the Changes in Calcitonin Gene-Related Peptide Seen in the Headache Phase of Migraine. <i>Cephalalgia</i> , 1991, 11, 3-4.	3.9	78
247	Serotonin 5-HT <sub>1B/1D</sub> Receptor Agonists in Migraine. <i>CNS Drugs</i> , 1998, 10, 271-286.	5.9	78
248	Placebo Response in Cluster Headache Trials: A Review. <i>Cephalalgia</i> , 2003, 23, 504-510.	3.9	78
249	Evidence for an X-linked genetic component in familial typical migraine. <i>Human Molecular Genetics</i> , 1998, 7, 459-463.	2.9	77
250	Calcitonin Gene-Related Peptide Antagonists as Treatments of Migraine and Other Primary Headaches. <i>Drugs</i> , 2005, 65, 2557-2567.	10.9	76
251	Neurostimulation approaches to primary headache disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 262-268.	3.6	76
252	Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. <i>Cephalalgia</i> , 2011, 31, 1343-1358.	3.9	76

#	ARTICLE	IF	CITATIONS
253	Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. <i>Neurotherapeutics</i> , 2018, 15, 304-312.	4.4	76
254	Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. <i>Brain Research</i> , 1989, 476, 71-77.	2.2	75
255	Sphenopalatine ganglion stimulation increases regional cerebral blood flow independent of glucose utilization in the cat. <i>Brain Research</i> , 1990, 506, 145-148.	2.2	75
256	Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. <i>Brain</i> , 1998, 121, 1231-1237.	7.6	75
257	Alopecia and cutaneous atrophy after greater occipital nerve infiltration with corticosteroid. <i>Neurology</i> , 2004, 63, 2193-2194.	1.1	75
258	Trigeminal Autonomic Cephalalgias: Current and Future Treatments. <i>Headache</i> , 2007, 47, 969-980.	3.9	75
259	The origin of nausea in migraine—A PET study. <i>Journal of Headache and Pain</i> , 2014, 15, 84.	6.0	75
260	SUNCT syndrome: Prolonged attacks, refractoriness and response to topiramate. <i>Neurology</i> , 2002, 58, 1307-1307.	1.1	74
261	The Role of Melatonin in the Treatment of Primary Headache Disorders. <i>Headache</i> , 2016, 56, 1257-1266.	3.9	74
262	Occipital nerve stimulation in medically intractable, chronic cluster headache. The ICON study: Rationale and protocol of a randomised trial. <i>Cephalalgia</i> , 2013, 33, 1238-1247.	3.9	73
263	New onset migraine with a brain stem cavernous angioma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 680-681.	1.9	72
264	Anatomy and Physiology of Pain Referral Patterns in Primary and Cervicogenic Headache Disorders. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005, 2, 42-48.	0.7	72
265	Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2019, 39, 817-826.	3.9	72
266	Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. <i>Brain Research</i> , 1988, 453, 143-149.	2.2	71
267	Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. <i>Brain Research</i> , 2000, 875, 119-124.	2.2	71
268	SUNCT syndrome secondary to prolactinoma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1590-1592.	1.9	71
269	Double-Blind Clinical Trials of Oral Triptans <i>Vs</i> Other Classes of Acute Migraine Medication â€” A Review. <i>Cephalalgia</i> , 2004, 24, 321-332.	3.9	71
270	Evidence for orexinergic mechanisms in migraine. <i>Neurobiology of Disease</i> , 2015, 74, 137-143.	4.4	71



#	ARTICLE	IF	CITATIONS
271	Effect of the Adenosine A1 Receptor Agonist Gr79236 on Trigeminal Nociception with Blink Reflex Recordings in Healthy Human Subjects. <i>Cephalalgia</i> , 2003, 23, 287-292.	3.9	70
272	Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. <i>Brain Research</i> , 2005, 1045, 1-11.	2.2	70
273	Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. <i>Current Opinion in Neurology</i> , 2008, 21, 323-330.	3.6	70
274	Photic hypersensitivity in the premonitory phase of migraine – a positron emission tomography study. <i>European Journal of Neurology</i> , 2014, 21, 1178-1183.	3.3	70
275	Migraine, Allodynia, Sensitisation and All of That .... <i>European Neurology</i> , 2005, 53, 10-16.	1.4	69
276	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487.	3.9	69
277	Chronic daily headache: nosology and pathophysiology. <i>Current Opinion in Neurology</i> , 2002, 15, 287-295.	3.6	68
278	Topiramate inhibits trigeminovascular activation: an intravital microscopy study. <i>British Journal of Pharmacology</i> , 2005, 146, 7-14.	5.4	68
279	Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. <i>Neuroscience Letters</i> , 2006, 403, 73-77.	2.1	68
280	Occipital Nerve Stimulation for Headache: Mechanisms and Efficacy. <i>Headache</i> , 2008, 48, 313-318.	3.9	68
281	Changes in Neurocognitive Architecture in Patients with Obstructive Sleep Apnea Treated with Continuous Positive Airway Pressure. <i>EBioMedicine</i> , 2016, 7, 221-229.	6.1	68
282	Stimulation of the Trigeminal ganglion increases flow in the extracerebral but not the cerebral circulation of the monkey. <i>Brain Research</i> , 1986, 381, 63-67.	2.2	67
283	Autonomic nervous system control of the cerebral circulation. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 193-201.	1.8	67
284	A potential nitrenergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. <i>Journal of Headache and Pain</i> , 2010, 11, 477-483.	6.0	66
285	Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for <sup>11</sup> C-dihydroergotamine during glyceryl trinitrate-induced migraine. <i>Brain</i> , 2016, 139, 1994-2001.	7.6	66
286	Fortnightly Review: Diagnosis and management of migraine. <i>BMJ: British Medical Journal</i> , 1996, 312, 1279-1283.	2.3	66
287	Therapeutic potential of novel glutamate receptor antagonists in migraine. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 789-803.	4.1	65
288	Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. <i>Headache</i> , 2018, 58, 1658-1669.	3.9	65

#	ARTICLE	IF	CITATIONS
289	Transcranial Magnetic Stimulation for Pain, Headache, and Comorbid Depression: INS-NANS Expert Consensus Panel Review and Recommendation. <i>Neuromodulation</i> , 2020, 23, 267-290.	0.8	65
290	Effects of locus coeruleus stimulation on carotid vascular resistance in the cat. <i>Brain Research</i> , 1983, 278, 175-183.	2.2	64
291	Can we Develop Neurally Acting Drugs for the Treatment of Migraine?. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 741-750.	46.4	64
292	Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. <i>Pain</i> , 2005, 117, 30-39.	4.2	64
293	Update on the prophylaxis of migraine. <i>Current Treatment Options in Neurology</i> , 2008, 10, 20-29.	1.8	64
294	GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. <i>Neurobiology of Disease</i> , 2010, 37, 314-323.	4.4	63
295	A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room. <i>Neurohospitalist</i> , The, 2012, 2, 51-59.	0.8	63
296	The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. <i>Neurology</i> , 2015, 84, 1043-1050.	1.1	63
297	Variability of clinical features in attacks of migraine with aura. <i>Cephalalgia</i> , 2016, 36, 216-224.	3.9	63
298	Visual snow syndrome: what we know so far. <i>Current Opinion in Neurology</i> , 2018, 31, 52-58.	3.6	63
299	Before the headache. <i>Neurology</i> , 2012, 79, 1392-1396.	1.1	62
300	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. <i>Journal of Neuroscience</i> , 2015, 35, 13800-13806.	3.6	62
301	Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. <i>Brain</i> , 2019, 142, 103-119.	7.6	62
302	Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. <i>Current Opinion in Neurology</i> , 2020, 33, 309-315.	3.6	62
303	How do the Currently Used Prophylactic Agents Work in Migraine?. <i>Cephalalgia</i> , 1997, 17, 85-92.	3.9	61
304	The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. <i>European Journal of Pharmacology</i> , 2002, 452, 223-228.	3.5	61
305	The Premonitory Phase of Migraine – What Can We Learn From It?. <i>Headache</i> , 2015, 55, 609-620.	3.9	61
306	Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2018, 58, 933-947.	3.9	61

#	ARTICLE	IF	CITATIONS
307	Migraine progression in subgroups of migraine based on comorbidities. <i>Neurology</i> , 2019, 93, e2224-e2236.	1.1	60
308	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. <i>Cephalalgia</i> , 2019, 39, 665-673.	3.9	60
309	The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. <i>Cephalalgia</i> , 2011, 31, 1116-1130.	3.9	59
310	Calcitonin gene-related peptide and migraine. <i>Current Opinion in Neurology</i> , 2015, 28, 250-254.	3.6	59
311	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. <i>Lancet Neurology</i> , The, 2022, 21, 284-294.	10.2	59
312	Animal models of headache: from bedside to bench and back to bedside. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 389-411.	2.8	58
313	Acute Migraine Therapy: New Drugs and New Approaches. <i>Current Treatment Options in Neurology</i> , 2011, 13, 1-14.	1.8	58
314	Triptan nonresponders: Do they exist and who are they?. <i>Cephalalgia</i> , 2013, 33, 891-896.	3.9	58
315	Structural and functional footprint of visual snow syndrome. <i>Brain</i> , 2020, 143, 1106-1113.	7.6	58
316	The peripheral pathway for extracranial vasodilatation in the cat. <i>Journal of the Autonomic Nervous System</i> , 1984, 10, 145-155.	1.9	57
317	Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5ht1b/1Dreceptor: A central action in migraine?. <i>Annals of Neurology</i> , 1998, 43, 711-718.	5.3	57
318	Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. <i>Pain</i> , 1999, 82, 15-22.	4.2	57
319	The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. <i>Brain Research</i> , 2001, 907, 117-124.	2.2	57
320	Distribution of 5-HT1B, 5-HT1D and 5-HT1F receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans. <i>Brain Research</i> , 2010, 1361, 76-85.	2.2	57
321	Cluster headache: Epidemiology, pathophysiology, clinical features, and diagnosis. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 3.	0.5	57
322	Recent advances in the diagnosis and management of migraine. <i>BMJ: British Medical Journal</i> , 2006, 332, 25-29.	2.3	55
323	Stimulation of an intracranial trigeminally-innervated structure selectively increases cerebral blood flow1These data were presented in part at the XVIIth International Symposium on Cerebral Blood Flow and Metabolism, Cologne, July, 1995 [27].1. <i>Brain Research</i> , 1997, 751, 247-252.	2.2	54
324	Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. <i>Neuropeptides</i> , 1999, 33, 41-46.	2.2	54

#	ARTICLE	IF	CITATIONS
325	Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?. Expert Opinion on Investigational Drugs, 2010, 19, 555-561.	4.1	54
326	The typical duration of migraine aura: A systematic review. Cephalalgia, 2013, 33, 483-490.	3.9	54
327	Migraine among medical students in Kuwait University. Journal of Headache and Pain, 2014, 15, 26.	6.0	54
328	Persistent and Repetitive Visual Disturbances in Migraine: A Review. Headache, 2017, 57, 1-16.	3.9	54
329	Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs, 2018, 78, 411-437.	10.9	54
330	What has functional neuroimaging done for primary headache and for the clinical neurologist?. Journal of Clinical Neuroscience, 2010, 17, 547-553.	1.5	53
331	Update on intracranial hypertension and hypotension. Current Opinion in Neurology, 2013, 26, 240-247.	3.6	53
332	Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. Lancet Neurology, The, 2019, 18, 1081-1090.	10.2	53
333	Zolmitriptan, a 5-HT <sub>1B/1D</sub> receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. European Journal of Neurology, 1998, 5, 535-543.	3.3	52
334	Introduction: On the Functional Neuroanatomy of Neck Pain. Cephalalgia, 2008, 28, 1-7.	3.9	52
335	New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Current Treatment Options in Neurology, 2012, 14, 50-59.	1.8	52
336	Outcomes of Greater Occipital Nerve Injections in Pediatric Patients With Chronic Primary Headache Disorders. Pediatric Neurology, 2014, 50, 135-139.	2.1	52
337	Hypothalamic involvement and activation in cluster headache. Current Pain and Headache Reports, 2001, 5, 60-66.	2.9	51
338	Trigeminal antinociception induced by bicuculline in the periaqueductal gray (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neuroscience Letters, 2003, 336, 113-116.	2.1	51
339	The mechanism of cerebrovascular vasoconstriction in response to locus coeruleus stimulation. Brain Research, 1985, 326, 213-217.	2.2	50
340	A simple method, using 2-hydroxypropyl- $\beta$ -cyclodextrin, of administering $\beta$ -chloralose at room temperature. Journal of Neuroscience Methods, 1997, 77, 49-53.	2.5	50
341	Amylin: Localization, Effects on Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. Scientific World Journal, The, 2001, 1, 168-180.	2.1	50
342	Emerging therapies for migraine. Nature Clinical Practice Neurology, 2007, 3, 610-619.	2.5	50

#	ARTICLE	IF	CITATIONS
343	The "Act When Mild" (AWM) Study: A Step Forward in Our Understanding of Early Treatment in Acute Migraine. <i>Cephalgia</i> , 2008, 28, 36-41.	3.9	50
344	Secondary cluster headache responsive to sumatriptan.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 59, 633-634.	1.9	49
345	"Paratrigeminal" paralysis of the oculopupillary sympathetic system. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 297-299.	1.9	49
346	Imaging patients with suspected brain tumour: guidance for primary care. <i>British Journal of General Practice</i> , 2008, 58, 880-885.	1.4	49
347	Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial. <i>Cephalgia</i> , 2018, 38, 1554-1563.	3.9	49
348	Gray matter volume modifications in migraine. <i>Neurology</i> , 2018, 91, e280-e292.	1.1	49
349	Comparison of More and Less Lipophilic Serotonin (5HT1B/1D) Agonists in a Model of Trigeminovascular Nociception in Cat. <i>Experimental Neurology</i> , 1998, 150, 45-51.	4.1	48
350	Zolmitriptan Intranasal: A Review of the Pharmacokinetics and Clinical Efficacy. <i>Headache</i> , 2006, 46, 138-149.	3.9	48
351	Migraine aura symptoms: Duration, succession and temporal relationship to headache. <i>Cephalgia</i> , 2016, 36, 413-421.	3.9	48
352	An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine. <i>Headache</i> , 2017, 57, 685-691.	3.9	48
353	Calcitonin gene-related peptide: A molecular link between obesity and migraine?. <i>Drug News and Perspectives</i> , 2010, 23, 112.	1.5	48
354	Plasma neuropeptide Y in the symptomatic limb of patients with causalgic pain. <i>Clinical Autonomic Research</i> , 1994, 4, 113-116.	2.5	47
355	The Paroxysmal Hemicrania-Tic Syndrome. <i>Cephalgia</i> , 2003, 23, 24-28.	3.9	47
356	Secondary "hypnic headache". <i>Journal of Neurology</i> , 2007, 254, 646-654.	3.6	47
357	Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. <i>Headache</i> , 2009, 49, S21-33.	3.9	47
358	Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. <i>Cephalgia</i> , 2015, 35, 1298-1307.	3.9	47
359	Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. <i>Journal of Headache and Pain</i> , 2017, 18, 109.	6.0	47
360	Inhibition of calcitonin gene-related peptide by h-CGRP(8-37) antagonizes the cerebral dilator response from nasociliary nerve stimulation in the cat. <i>Neuroscience Letters</i> , 1993, 151, 13-16.	2.1	46

#	ARTICLE	IF	CITATIONS
361	Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na <sup>+</sup> ion channel blockade. <i>Brain Research</i> , 2008, 1229, 27-36.	2.2	46
362	Comparative tolerability of treatments for acute migraine: A network meta-analysis. <i>Cephalalgia</i> , 2017, 37, 965-978.	3.9	46
363	Imaging the Visual Network in the Migraine Spectrum. <i>Frontiers in Neurology</i> , 2019, 10, 1325.	2.4	46
364	Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 296-306.	3.7	46
365	Mechanisms of action of serotonin 5-HT <sub>1B/D</sub> agonists: insights into migraine pathophysiology using rizatriptan. <i>Neurology</i> , 2000, 55, S8-14.	1.1	46
366	Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 274-277.	2.1	45
367	Divergent influences of the locus coeruleus on migraine pathophysiology. <i>Pain</i> , 2019, 160, 385-394.	4.2	45
368	Cluster headache pathophysiology – insights from current and emerging treatments. <i>Nature Reviews Neurology</i> , 2021, 17, 308-324.	10.1	45
369	Intracranial Vessels in Trigeminal Transmitted Pain: A PET Study. <i>NeuroImage</i> , 1999, 9, 453-460.	4.2	44
370	The trigeminovascular system does not require a peripheral sensory input to be activated – migraine is a central disorder Focus on –Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. <i>Cephalalgia</i> , 2012, 32, 3-5.	3.9	44
371	Migraine misdiagnosis as a sinusitis, a delay that can last for many years. <i>Journal of Headache and Pain</i> , 2013, 14, 97.	6.0	44
372	Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service. <i>Journal of Headache and Pain</i> , 2016, 17, 94.	6.0	44
373	Recent advances in headache neuroimaging. <i>Current Opinion in Neurology</i> , 2018, 31, 379-385.	3.6	44
374	Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. <i>Headache</i> , 2021, 61, 992-1003.	3.9	44
375	Phenotype of patients responsive to occipital nerve stimulation for refractory head pain. <i>Cephalalgia</i> , 2010, 30, 662-73.	3.9	44
376	Evidence for postjunctional serotonin (5-HT <sub>1</sub> ) receptors in the trigeminocervical complex. <i>Annals of Neurology</i> , 2001, 50, 804-807.	5.3	43
377	Central Mechanisms of Peripheral Nerve Stimulation in Headache Disorders. <i>Progress in Neurological Surgery</i> , 2011, 24, 16-26.	1.3	43
378	Emerging Targets in Migraine. <i>CNS Drugs</i> , 2014, 28, 11-17.	5.9	43

#	ARTICLE	IF	CITATIONS
379	Deficits in the function of small and large afferent fibers in confirmed cases of carpal tunnel syndrome. <i>Muscle and Nerve</i> , 1994, 17, 614-622.	2.2	42
380	Significance of atypical presentation of symptomatic SUNCT: a case report. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 244-246.	1.9	42
381	Intravital Microscopy on a Closed Cranial Window in Mice: A Model to Study Trigeminovascular Mechanisms Involved in Migraine. <i>Cephalalgia</i> , 2006, 26, 1294-1303.	3.9	42
382	Treatment-Emergent CNS Symptoms Following Triptan Therapy are Part of The Attack. <i>Cephalalgia</i> , 2007, 27, 254-262.	3.9	42
383	Trigeminal autonomic cephalalgias: Diagnosis and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 117-125.	4.2	42
384	What Happens to New-Onset Headache Presented to Primary Care? A Case-Cohort Study Using Electronic Primary Care Records. <i>Cephalalgia</i> , 2008, 28, 1188-1195.	3.9	42
385	Proposals for New Standardized General Diagnostic Criteria for the Secondary Headaches. <i>Cephalalgia</i> , 2009, 29, 1331-1336.	3.9	42
386	TRPV1 receptor blockade is ineffective in different <i>in vivo</i> models of migraine. <i>Cephalalgia</i> , 2011, 31, 172-180.	3.9	42
387	International Classification of Headache Disorders - ICHD-4 $\alpha$ . <i>Cephalalgia</i> , 2020, 40, 887-888.	3.9	42
388	Benign Cough Headache. <i>Cephalalgia</i> , 2002, 22, 772-779.	3.9	41
389	Neurostimulation in primary headache syndromes. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1785-1789.	2.8	41
390	Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. <i>British Journal of Pharmacology</i> , 2009, 157, 464-473.	5.4	41
391	Is migraine a risk factor for pediatric stroke?. <i>Cephalalgia</i> , 2015, 35, 1252-1260.	3.9	41
392	Variability of the characteristics of a migraine attack within patients. <i>Cephalalgia</i> , 2016, 36, 825-830.	3.9	41
393	One-year sustained efficacy of erenumab in episodic migraine. <i>Neurology</i> , 2020, 95, e469-e479.	1.1	41
394	Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. <i>Cephalalgia</i> , 2010, 30, 519-27.	3.9	41
395	PET demonstration of hypothalamic activation in cluster headache. <i>Neurology</i> , 1999, 52, 1522-1522.	1.1	41
396	High-frequency stimulation of the facial nerve results in local cortical release of vasoactive intestinal polypeptide in the anesthetised cat. <i>Neuroscience Letters</i> , 1990, 112, 282-289.	2.1	40

#	ARTICLE	IF	CITATIONS
397	Paroxysmal hemicrania responding to topiramate. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 96-97.	1.9	40
398	Positive Persistent Visual Symptoms (Visual Snow) Presenting as a Migraine Variant in a 12-Year-Old Girl. <i>Pediatric Neurology</i> , 2013, 49, 361-363.	2.1	40
399	The relationship between migraine and infant colic: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2015, 35, 63-72.	3.9	40
400	Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients: Table 1. <i>Brain</i> , 2016, 139, 2571-2577.	7.6	40
401	Neuroendocrine signaling modulates specific neural networks relevant to migraine. <i>Neurobiology of Disease</i> , 2017, 101, 16-26.	4.4	40
402	Migraine association and linkage studies of an endothelial nitric oxide synthase ( <i>NOS3</i> ) gene polymorphism. <i>Neurology</i> , 1997, 49, 614-617.	1.1	39
403	Occipital activation in glyceryl trinitrate induced migraine with visual aura. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1158-1160.	1.9	39
404	Identification of Negative Predictors of Pain-Free Response to Triptans: Analysis of the Eletriptan Database. <i>Cephalalgia</i> , 2008, 28, 35-40.	3.9	39
405	Defining Refractory Migraine: Results of the RHSIS Survey of American Headache Society Members. <i>Headache</i> , 2009, 49, 509-518.	3.9	39
406	Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches. <i>Cephalalgia</i> , 2010, 30, 761-766.	3.9	39
407	Medication Overuse in Children and Adolescents. <i>Current Pain and Headache Reports</i> , 2014, 18, 428.	2.9	39
408	Efficacy and mechanism of anticonvulsant drugs in migraine. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 191-201.	3.1	39
409	Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. <i>Cephalalgia</i> , 2019, 39, 1753-1761.	3.9	39
410	PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?. <i>Pain</i> , 2020, 161, 1670-1681.	4.2	39
411	Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. <i>Journal of the Autonomic Nervous System</i> , 1994, 49, 97-103.	1.9	38
412	Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. <i>Neuroscience</i> , 1998, 86, 337-343.	2.3	38
413	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. <i>Headache</i> , 2001, 41, 754-763.	3.9	38
414	SUNCT Syndrome in the Elderly. <i>Cephalalgia</i> , 2004, 24, 508-509.	3.9	38



#	ARTICLE	IF	CITATIONS
415	Properties of neurons in the trigeminal nucleus caudalis responding to noxious dural and facial stimulation. <i>Brain Research</i> , 2005, 1046, 122-129.	2.2	38
416	CGRP Mechanism Antagonists and Migraine Management. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 25.	4.2	38
417	Aura and Head pain: relationship and gaps in the translational models. <i>Journal of Headache and Pain</i> , 2019, 20, 94.	6.0	38
418	Subcortical Cerebral Blood Flow and Metabolic Changes Elicited by Cortical Spreading Depression in Rat. <i>Cephalgia</i> , 1992, 12, 137-141.	3.9	37
419	Trigeminal autonomic cephalalgias. Pathophysiology and classification. <i>Revue Neurologique</i> , 2005, 161, 692-695.	1.5	37
420	Neuroimaging of migraine. <i>Current Pain and Headache Reports</i> , 2006, 10, 221-224.	2.9	37
421	Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. <i>Pain</i> , 2016, 157, 1666-1673.	4.2	37
422	Differential medication overuse risk of novel anti-migraine therapeutics. <i>Brain</i> , 2020, 143, 2681-2688.	7.6	37
423	The Scientific Basis of Medication Choice in Symptomatic Migraine Treatment. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 20-26.	0.5	36
424	GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. <i>British Journal of Pharmacology</i> , 2001, 134, 896-904.	5.4	36
425	Migraine: diagnosis and management. <i>Internal Medicine Journal</i> , 2003, 33, 436-442.	0.8	36
426	Medication-overuse headache in patients with cluster headache. <i>Current Pain and Headache Reports</i> , 2008, 12, 122-127.	2.9	36
427	Comparison of the Effects of Central and Peripheral Dopamine Receptor Activation on Evoked Firing in the Trigemincervical Complex. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 752-763.	2.5	36
428	New Daily Persistent Headache: A Syndrome Not a Discrete Disorder. <i>Headache</i> , 2011, 51, 650-653.	3.9	36
429	Headache-related health resource utilisation in chronic and episodic migraine across six countries. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1309-1317.	1.9	36
430	Functional neuroimaging of primary headache disorders. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 105-110.	4.2	35
431	Epidemiology, Risk Factors, and Treatment of Chronic Migraine: A Focus on Topiramate. <i>Headache</i> , 2008, 48, 1087-1095.	3.9	35
432	Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. <i>Neurology</i> , 2010, 75, 1098-1103.	1.1	35

#	ARTICLE	IF	CITATIONS
433	Trigemino-cervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. <i>Pain</i> , 2011, 152, 2365-2376.	4.2	35
434	The migraine postdrome. <i>Current Opinion in Neurology</i> , 2016, 29, 299-301.	3.6	35
435	Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study. <i>Headache</i> , 2018, 58, 724-731.	3.9	35
436	Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. <i>Journal of Headache and Pain</i> , 2018, 19, 5.	6.0	35
437	Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. <i>Cephalalgia</i> , 2019, 39, 967-977.	3.9	35
438	Occipital cortex and cerebellum gray matter changes in visual snow syndrome. <i>Neurology</i> , 2020, 95, e1792-e1799.	1.1	35
439	Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat. <i>Neuroscience</i> , 2005, 135, 203-212.	2.3	34
440	Triptans in Orgasmic Headache. <i>Cephalalgia</i> , 2006, 26, 1458-1461.	3.9	34
441	Almotriptan and zolmitriptan in the acute treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 34-40.	2.1	34
442	Metabotropic glutamate receptor 5: a target for migraine therapy. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 560-571.	3.7	34
443	Are some patient-perceived migraine triggers simply early manifestations of the attack?. <i>Journal of Neurology</i> , 2021, 268, 1885-1893.	3.6	34
444	Migraine Association and Linkage Analyses of the Human 5-Hydroxytryptamine (5HT <sub>2A</sub> ) Receptor Gene. <i>Cephalalgia</i> , 1996, 16, 463-467.	3.9	33
445	4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT <sub>1B/1D</sub> receptor agonist activity?. <i>Neuropharmacology</i> , 2001, 40, 520-525.	4.1	33
446	Familial SUNCT. <i>Cephalalgia</i> , 2005, 25, 457-459.	3.9	33
447	Verapamil induced gingival enlargement in cluster headache. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 124-127.	1.9	33
448	Neuropsychiatric Side-Effects of Lidocaine: Examples from the Treatment of Headache and a Review. <i>Cephalalgia</i> , 2009, 29, 496-508.	3.9	33
449	Visual Snow – Persistent Positive Visual Phenomenon Distinct from Migraine Aura. <i>Current Pain and Headache Reports</i> , 2015, 19, 23.	2.9	33
450	Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. <i>JAMA Neurology</i> , 2017, 74, 1266.	9.0	33

#	ARTICLE	IF	CITATIONS
451	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021, 61, 263-275.	3.9	33
452	New Generation Gepants: Migraine Acute and Preventive Medications. <i>Journal of Clinical Medicine</i> , 2022, 11, 1656.	2.4	33
453	Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1987, 253, R270-R274.	1.8	32
454	Clinicopathological correlation in a case of painful ophthalmoplegia: Tolosa-Hunt syndrome.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 1290-1293.	1.9	32
455	The role of histamine in dural vessel dilation. <i>Brain Research</i> , 2002, 956, 96-102.	2.2	32
456	How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. <i>Current Medical Research and Opinion</i> , 2005, 21, 413-424.	1.9	32
457	Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Meta-Analysis of Two Studies. <i>Headache</i> , 2009, 49, 1315-1323.	3.9	32
458	Targeting CGRP and 5-HT <sub>1F</sub> Receptors for the Acute Therapy of Migraine: A Literature Review. <i>Headache</i> , 2019, 59, 3-19.	3.9	32
459	The effect of adrenergic compounds on neurogenic dural vasodilatation. <i>European Journal of Pharmacology</i> , 2001, 424, 53-58.	3.5	31
460	Chronic headache and pituitary tumors. <i>Current Pain and Headache Reports</i> , 2008, 12, 74-78.	2.9	31
461	Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. <i>European Journal of Neurology</i> , 2018, 25, 811-817.	3.3	31
462	Disrupted connectivity within visual, attentional and salience networks in the visual snow syndrome. <i>Human Brain Mapping</i> , 2021, 42, 2032-2044.	3.6	31
463	Practical management of medication-overuse headache. <i>Acta Neurologica Belgica</i> , 2006, 106, 43-51.	1.1	31
464	Octreotide is not Effective in the Acute Treatment of Migraine. <i>Cephalalgia</i> , 2005, 25, 48-55.	3.9	30
465	Functional neuroimaging of primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1159-1171.	2.8	30
466	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. <i>Headache</i> , 2007, 48, 070629211050002-???.	3.9	30
467	The Long Drought: The Dearth of Public Funding for Headache Research. <i>Cephalalgia</i> , 2007, 27, 991-994.	3.9	30
468	Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. <i>Cephalalgia</i> , 2011, 31, 1368-1380.	3.9	30

#	ARTICLE	IF	CITATIONS
469	New daily persistent headache. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72 Suppl 2, ii6-ii9.	1.9	30
470	The Hospital Management of Severe Migrainous Headache. <i>Headache</i> , 1991, 31, 658-660.	3.9	29
471	Neuroimaging in headache. <i>Microscopy Research and Technique</i> , 2001, 53, 179-187.	2.2	29
472	Functional brain imaging in hemicrania continua: Implications for nosology and pathophysiology. <i>Current Pain and Headache Reports</i> , 2005, 9, 281-288.	2.9	29
473	Is medication-overuse headache a distinct biological entity?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 401-401.	2.5	29
474	Update on Hemicrania Continua. <i>Current Pain and Headache Reports</i> , 2011, 15, 51-56.	2.9	29
475	Treatment of Pediatric Migraine in the Emergency Room. <i>Pediatric Neurology</i> , 2012, 47, 233-241.	2.1	29
476	Cutaneous Sensory Stimulation Leading to Facial Flushing and Release of Calcitonin Gene-Related Peptide. <i>Cephalalgia</i> , 1992, 12, 53-56.	3.9	28
477	Calcitonin gene-related peptide (CGRP) antagonists and migraine. <i>Neurology</i> , 2008, 70, 1300-1301.	1.1	28
478	Inhibition of trigeminovascular dural nociceptive afferents by Ca <sup>2+</sup> -activated K <sup>+</sup> (MaxiK/BKCa) channel opening. <i>Pain</i> , 2010, 151, 128-136.	4.2	28
479	Reduced efficacy of sumatriptan in migraine with aura vs without aura. <i>Neurology</i> , 2015, 84, 1880-1885.	1.1	28
480	Trigeminal autonomic cephalalgias. <i>Oral Diseases</i> , 2016, 22, 1-8.	3.0	28
481	Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. <i>European Journal of Neurology</i> , 2020, 27, 609-618.	3.3	28
482	Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study. <i>Cephalalgia</i> , 2020, 40, 828-841.	3.9	28
483	Systematic review of outcomes and endpoints in preventive migraine clinical trials. <i>Headache</i> , 2021, 61, 253-262.	3.9	28
484	Coincidence of Familial Hemiplegic Migraine and Hemicrania Continua? A Case Report. <i>Cephalalgia</i> , 1999, 19, 533-535.	3.9	27
485	Acromegaly: A Unique Human Headache Model. <i>Headache</i> , 2003, 43, 794-797.	3.9	27
486	To scan or not to scan in headache. <i>BMJ: British Medical Journal</i> , 2004, 329, 469-470.	2.3	27

#	ARTICLE	IF	CITATIONS
487	Managing cluster headache. <i>Practical Neurology</i> , 2019, 19, 521-528.	1.1	27
488	Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 939-944.	1.9	27
489	CGRP – a target for acute therapy in migraine: Clinical data. <i>Cephalalgia</i> , 2019, 39, 420-427.	3.9	27
490	Cluster headache: imaging and other developments. <i>Current Opinion in Neurology</i> , 1998, 11, 199-203.	3.6	27
491	Wilfred Harris' Early Description of Cluster Headache. <i>Cephalalgia</i> , 2002, 22, 320-326.	3.9	26
492	Lacrimation, conjunctival injection, nasal symptoms... cluster headache, migraine and cranial autonomic symptoms in primary headache disorders–what's new?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1057-1058.	1.9	26
493	Recent Advances in Pharmacotherapy for Episodic Migraine. <i>CNS Drugs</i> , 2019, 33, 1053-1071.	5.9	26
494	Extracerebral manifestations in migraine. A peptidergic involvement?. <i>Journal of Internal Medicine</i> , 1990, 228, 299-304.	6.0	25
495	The Clinical Profile of Sumatriptan: Cluster Headache. <i>European Neurology</i> , 1994, 34, 35-39.	1.4	25
496	Home-Based Trials in Adolescent Migraine. <i>JAMA Neurology</i> , 2017, 74, 744.	9.0	25
497	Primary headache disorders. <i>Neurology: Clinical Practice</i> , 2019, 9, 233-240.	1.6	25
498	Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. <i>British Journal of Pharmacology</i> , 2020, 177, 2478-2486.	5.4	25
499	Long-term Efficacy and Safety of Erenumab. <i>Neurology</i> , 2021, 96, .	1.1	25
500	Short-lasting primary headaches: focus on trigeminal autonomic cephalgias and indomethacin-sensitive headaches. <i>Current Opinion in Neurology</i> , 1999, 12, 273-277.	3.6	25
501	Acquired Immunodeficiency Syndrome (AIDS) and Sulfadiazine-Associated Acute Renal Failure. <i>Annals of Internal Medicine</i> , 1987, 107, 783.	3.9	24
502	New targets in the acute treatment of headache. <i>Current Opinion in Neurology</i> , 2005, 18, 283-288.	3.6	24
503	Trigeminal autonomic cephalgias: fancy term or constructive change to the IHS classification?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 301-305.	1.9	24
504	Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2. <i>Neurobiology of Disease</i> , 2008, 32, 10-15.	4.4	24

#	ARTICLE	IF	CITATIONS
505	Large Conductance Calcium-Activated Potassium Channels (BKCa) Modulate Trigemino-vascular Nociceptive Transmission. <i>Cephalalgia</i> , 2009, 29, 1242-1258.	3.9	24
506	MRI in headache. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 263-273.	2.8	24
507	Experts'™ opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. <i>Journal of Headache and Pain</i> , 2017, 18, 113.	6.0	24
508	Imaging the Premonitory Phase of Migraine. <i>Frontiers in Neurology</i> , 2020, 11, 140.	2.4	24
509	Mechanisms of Cluster Headache: Table 1.. <i>Cephalalgia</i> , 1999, 19, 19-23.	3.9	23
510	Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. <i>British Journal of Pharmacology</i> , 2003, 138, 317-324.	5.4	23
511	TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. <i>Acta Neurologica Scandinavica</i> , 2004, 110, 137-143.	2.1	23
512	GABAA receptor modulation of trigemino-vascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. <i>Brain Research</i> , 2004, 1013, 188-193.	2.2	23
513	The Association between Calcitonin Gene-Related Peptide (CGRP), Substance P and Headache in Pituitary Tumours. <i>Pituitary</i> , 2004, 7, 67-71.	2.9	23
514	Sensory information processing may be neuroenergetically more demanding in migraine patients. <i>NeuroReport</i> , 2013, 24, 202-205.	1.2	23
515	New Targets for Migraine Therapy. <i>Current Treatment Options in Neurology</i> , 2014, 16, 318.	1.8	23
516	Current Approaches to Neuromodulation in Primary Headaches: Focus on Vagal Nerve and Sphenopalatine Ganglion Stimulation. <i>Current Pain and Headache Reports</i> , 2016, 20, 47.	2.9	23
517	The subcortical belly of sleep: New possibilities in neuromodulation of basal ganglia?. <i>Sleep Medicine Reviews</i> , 2020, 52, 101317.	8.5	23
518	Headache-related disability in the management of migraine. <i>Neurology</i> , 2001, 56, S1-3.	1.1	23
519	Evaluation of treatment response and symptom progression in 400 patients with visual snow syndrome. <i>British Journal of Ophthalmology</i> , 2022, 106, 1318-1324.	3.9	23
520	Brainstem activation of the adrenal medulla in the cat. <i>Brain Research</i> , 1985, 327, 241-248.	2.2	22
521	Time-To-Event Analysis, Or Who Gets Better Sooner? an Emerging Concept in Headache Study Methodology. <i>Cephalalgia</i> , 1999, 19, 552-556.	3.9	22
522	Vasodilator Agents and Supracollicular Transection Fail To Inhibit Cortical Spreading Depression in the Cat. <i>Cephalalgia</i> , 1999, 19, 592-597.	3.9	22

#	ARTICLE	IF	CITATIONS
523	4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses. <i>Neuropharmacology</i> , 2001, 40, 911-917.	4.1	22
524	Bilateral Paroxysmal Hemicrania or Bilateral Paroxysmal Cephalgia, Another Novel Indomethacin-Responsive Primary Headache Syndrome?. <i>Cephalgia</i> , 2005, 25, 79-81.	3.9	22
525	The use of multiattribute decision models in evaluating triptan treatment options in migraine. <i>Journal of Neurology</i> , 2005, 252, 1026-1032.	3.6	22
526	Migraine: emerging treatment options for preventive and acute attack therapy. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 419-427.	2.4	22
527	Cluster headache: A review of neuroimaging findings. <i>Current Pain and Headache Reports</i> , 2007, 11, 131-136.	2.9	22
528	Trigeminal Autonomic Cephalalgias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 883-895.	0.8	22
529	Therapeutic prospects for migraine: Can paradise be regained?. <i>Annals of Neurology</i> , 2013, 74, 423-434.	5.3	22
530	Migraine and multiple sclerosis: Epidemiology and approach to treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 73-79.	2.0	22
531	Migraine triggers. <i>Neurology</i> , 2013, 80, 424-425.	1.1	22
532	Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors. <i>Pain</i> , 2015, 156, 439-450.	4.2	22
533	Cyclic alternating pattern in obstructive sleep apnea: A preliminary study. <i>Journal of Sleep Research</i> , 2021, 30, e13350.	3.2	22
534	Migraine Is More Than Just Headache: Is the Link to Chronic Fatigue and Mood Disorders Simply Due to Shared Biological Systems?. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 646692.	2.0	22
535	The Migraine Premonitory Phase. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 996-1008.	0.8	22
536	Lignocaine and headache: An electrophysiological study in the cat with supporting clinical observations in man. <i>Journal of Neurology</i> , 1994, 241, 415-420.	3.6	21
537	Characterization of Endothelin Receptors in the Cerebral Vasculature and Their Lack of Effect on Spreading Depression. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 698-704.	4.3	21
538	On the functional anatomy of migraine. <i>Annals of Neurology</i> , 1998, 43, 272-272.	5.3	21
539	Motion sickness, migraine, and menstruation in mariners. <i>Lancet, The</i> , 1998, 351, 1106.	13.7	21
540	CLUSTER AND RELATED HEADACHES. <i>Medical Clinics of North America</i> , 2001, 85, 997-1016.	2.5	21

#	ARTICLE	IF	CITATIONS
541	The ORL-1 (NOP1) receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic dural vasodilatation in the rat. <i>Neuropharmacology</i> , 2002, 43, 991-998.	4.1	21
542	Post-triptan era for the treatment of acute migraine. <i>Current Pain and Headache Reports</i> , 2004, 8, 393-398.	2.9	21
543	Paroxysmal Hemicrania in a Family. <i>Cephalalgia</i> , 2006, 26, 486-488.	3.9	21
544	Child Neurology: Migraine with aura in children. <i>Neurology</i> , 2010, 75, e16-9.	1.1	21
545	Trigeminal Neuropathic Pain in a Patient With Progressive Facial Hemiatrophy (Parry-Romberg) Tj ETQq1 1 0.784314 rgBT /Overlock 10 4.5	4.5	21
546	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. <i>Neurobiology of Disease</i> , 2014, 64, 1-7.	4.4	21
547	Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. II. The cat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1985, 248, R263-R269.	1.8	20
548	Effect of stimulation of facial nerve on regional cerebral blood flow and glucose utilization in cats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1989, 257, R517-R521.	1.8	20
549	Advances in the Pharmacotherapy of Migraine. <i>Drugs in R and D</i> , 1999, 2, 361-374.	2.2	20
550	The Hemicrania Continua Diagnosis. <i>Cephalalgia</i> , 2002, 22, 563-564.	3.9	20
551	Advances in the understanding of headache. <i>British Medical Bulletin</i> , 2005, 73-74, 83-92.	6.9	20
552	Cortical Spreading Depressionâ€”Better Understanding and More Questions. Focus on â€œDistinct Vascular Conduction With Cortical Spreading Depressionâ€• <i>Journal of Neurophysiology</i> , 2007, 97, 3827-3827.	1.8	20
553	Prolonged migraine aura: new insights from a prospective diary-aided study. <i>Journal of Headache and Pain</i> , 2018, 19, 77.	6.0	20
554	Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack. <i>Headache</i> , 2020, 60, 1244-1258.	3.9	20
555	Indomethacinâ€”responsive headachesâ€”A narrative review. <i>Headache</i> , 2021, 61, 700-714.	3.9	20
556	Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR project). <i>Clinical Therapeutics</i> , 2004, 26, 1533-1545.	2.5	19
557	The Role of Dopamine in a Model of Trigeminovascular Nociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 162-169.	2.5	19
558	Evaluation and Proposal for Optimization of Neurophysiological Tests In Migraine: Part 2â€”Neuroimaging and The Nitroglycerin Test. <i>Cephalalgia</i> , 2007, 27, 1339-1359.	3.9	19



#	ARTICLE	IF	CITATIONS
559	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. <i>Headache</i> , 2008, 48, 1399-1405.	3.9	19
560	MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments. <i>Mayo Clinic Proceedings</i> , 2011, 86, 948-955.	3.0	19
561	The Impact of Allodynia on the Efficacy of Almotriptan When Given Early in Migraine: Data From the "Act When Mild" Study. <i>International Journal of Neuroscience</i> , 2011, 121, 655-661.	1.6	19
562	Postoperative hemicrania continua-like headache - a case series. <i>Journal of Headache and Pain</i> , 2015, 16, 526.	6.0	19
563	Premonitory Symptoms of Migraine in Childhood and Adolescence. <i>Current Pain and Headache Reports</i> , 2017, 21, 34.	2.9	19
564	Comparative effects of traditional Chinese and Western migraine medicines in an animal model of nociceptive trigeminovascular activation. <i>Cephalalgia</i> , 2018, 38, 1215-1224.	3.9	19
565	21st century headache: mapping new territory. <i>Journal of Headache and Pain</i> , 2021, 22, 19.	6.0	19
566	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151.	3.9	19
567	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura. <i>JAMA Neurology</i> , 2022, 79, 159.	9.0	19
568	Characteristics of facial nerve-elicited cerebral vasodilatation determined using laser Doppler flowmetry. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1991, 260, R255-R262.	1.8	18
569	Cough headache responsive to methysergide. <i>Cephalalgia</i> , 1998, 18, 495-496.	3.9	18
570	Rizatriptan in Acute Treatment of Migraine: Update on New Comparative Data. <i>Cephalalgia</i> , 2000, 20, 10-15.	3.9	18
571	Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?. <i>Journal of Headache and Pain</i> , 2011, 12, 411-417.	6.0	18
572	The migraine postdrome: Spontaneous and triggered phenotypes. <i>Cephalalgia</i> , 2021, 41, 721-730.	3.9	18
573	Serotonin Receptor Ligands: Treatments of Acute Migraine and Cluster Headache. , 2007, , 129-143.		18
574	Examination of the involvement of neuropeptide Y (NPY) in cerebral autoregulation using the novel NPY antagonist PP56. <i>Neuropeptides</i> , 1993, 24, 27-33.	2.2	17
575	Neurogenic vasodilation of dural blood vessels is not mediated by cholinergic transmission in the anaesthetised rat. <i>European Journal of Pharmacology</i> , 2004, 493, 133-137.	3.5	17
576	Hypnic Headache. <i>Practical Neurology</i> , 2005, 5, 144-149.	1.1	17

#	ARTICLE	IF	CITATIONS
577	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. <i>Headache</i> , 2008, 48, 799-804.	3.9	17
578	Olvanil acts on transient receptor potential vanilloid channel 1 and cannabinoid receptors to modulate neuronal transmission in the trigeminovascular system. <i>Pain</i> , 2012, 153, 2226-2232.	4.2	17
579	Analysis of occipital nerve stimulation in studies of chronic migraine and broader implications of social media in clinical trials. <i>Cephalalgia</i> , 2013, 33, 214-215.	3.9	17
580	Incredible progress for an era of better migraine care. <i>Nature Reviews Neurology</i> , 2015, 11, 621-622.	10.1	17
581	Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. <i>Neurology</i> , 2016, 86, 856-859.	1.1	17
582	Neck-Tongue syndrome: A systematic review. <i>Cephalalgia</i> , 2018, 38, 374-382.	3.9	17
583	Localised increase in regional cerebral perfusion in patients with visual snow syndrome: a pseudo-continuous arterial spin labelling study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 918-926.	1.9	17
584	Differential actions of indomethacin: clinical relevance in headache. <i>Pain</i> , 2021, 162, 591-599.	4.2	17
585	The selective 5-HT <sub>1F</sub> receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. <i>British Journal of Pharmacology</i> , 2022, 179, 358-370.	5.4	17
586	Chronic tension-type headache: where are we?. <i>Brain</i> , 1999, 122, 1611-1612.	7.6	16
587	Exposure and isolation of the superior sagittal sinus elicits Fos in the trigeminal nucleus caudalis and dorsal horn of the cervical spinal cord: how long should you wait?. <i>Brain Research</i> , 1999, 824, 133-135.	2.2	16
588	Basilar artery aneurysm with autonomic features: an interesting pathophysiological problem. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 805-808.	1.9	16
589	Immunoreactivity of NOS, CGRP, PACAP, SP and VIP in the trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2 of the cat. <i>Journal of Headache and Pain</i> , 2003, 4, 156-163.	6.0	16
590	The relationship between neuropeptide Y expression and headache in pituitary tumours. <i>European Journal of Neurology</i> , 2006, 13, 125-129.	3.3	16
591	Cluster headache and the trigeminal-autonomic reflex: Driving or being driven?. <i>Cephalalgia</i> , 2018, 38, 1415-1417.	3.9	16
592	Discovery of CGRP in relation to migraine. <i>Cephalalgia</i> , 2019, 39, 331-332.	3.9	16
593	Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden. <i>Pharmacoeconomics</i> , 2021, 39, 357-372.	3.3	16
594	Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. <i>Brain Research</i> , 2021, 1770, 147629.	2.2	16

#	ARTICLE	IF	CITATIONS
595	Cerebral blood flow is not coupled to neuronal activity during stimulation of the facial nerve vasodilator system. <i>Brain Research</i> , 1994, 647, 192-198.	2.2	15
596	Naratriptan is effective and well tolerated in the acute treatment of migraine. <i>Neurology</i> , 1999, 52, 1300-1300.	1.1	15
597	Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. <i>Current Pain and Headache Reports</i> , 2004, 8, 435-442.	2.9	15
598	Another migraine gene. <i>Lancet, The</i> , 2005, 366, 345-346.	13.7	15
599	Trigeminal Autonomic Cephalalgias in Children and Adolescents: Cluster Headache and Related Conditions. <i>Seminars in Pediatric Neurology</i> , 2016, 23, 23-26.	2.0	15
600	<i>N</i>â€Methylâ€scpd</scpd>â€aspartate receptor openâ€channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. <i>European Journal of Neuroscience</i> , 2019, 50, 2847-2859.	2.6	15
601	Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. <i>Quality of Life Research</i> , 2019, 28, 2359-2372.	3.1	15
602	Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. <i>Medicine in Drug Discovery</i> , 2020, 7, 100053.	4.5	15
603	Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. <i>Cephalalgia</i> , 2021, 41, 546-560.	3.9	15
604	Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks. <i>Cephalalgia</i> , 2021, 41, 913-933.	3.9	15
605	Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. <i>Headache</i> , 2021, 61, 422-429.	3.9	15
606	Neuromodulatory approaches to the treatment of trigeminal autonomic cephalalgias. , 2007, 97, 99-110.		15
607	Two-year efficacy and safety of erenumab in participants with episodic migraine and 2â€4 prior preventive treatment failures: results from the LIBERTY study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 254-262.	1.9	15
608	Pressor response to electrical and chemical stimulation of nucleus raphe dorsalis in the cat.. <i>Stroke</i> , 1985, 16, 307-312.	2.0	14
609	Diagnosis and Optimum Treatment of Migraine. <i>CNS Drugs</i> , 1994, 1, 245-253.	5.9	14
610	Increasing the options for effective migraine management. <i>Neurology</i> , 1997, 48, S1-3.	1.1	14
611	Cluster Headache: New Perspectives. <i>Cephalalgia</i> , 1999, 19, 39-41.	3.9	14
612	Paroxysmal Hemicrania-Tic Syndrome. <i>Headache</i> , 2001, 41, 608-609.	3.9	14

#	ARTICLE	IF	CITATIONS
613	Treatment preferences and the selection of acute migraine medications: results from a population-based survey. <i>Journal of Headache and Pain</i> , 2004, 5, 123-130.	6.0	14
614	Migraine Aura. <i>Neuron</i> , 2004, 41, 679-680.	8.1	14
615	Stress, emotion and the heart: tako-tsubo cardiomyopathy. <i>Postgraduate Medical Journal</i> , 2006, 82, e29-e29.	1.8	14
616	Topiramate is likely to act outside of the trigeminocervical complex. <i>Cephalalgia</i> , 2013, 33, 291-300.	3.9	14
617	Predictors of Triptan Response in Pediatric Migraine. <i>Pediatric Neurology</i> , 2016, 58, 37-40.	2.1	14
618	Pediatric Migraine Prevention—First, Do No Harm. <i>JAMA Neurology</i> , 2017, 74, 893.	9.0	14
619	The Association Between Parental Migraine and Infant Colic: A Cross-sectional, Web-based, U.S. Survey Study. <i>Headache</i> , 2019, 59, 988-1001.	3.9	14
620	The Migraine Postdrome. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 1023-1031.	0.8	14
621	Trigeminal autonomic cephalgias (TACs). <i>Acta Neurologica Belgica</i> , 2001, 101, 10-9.	1.1	14
622	Trigeminal-Autonomic Cephalgias (TACs). <i>Cephalalgia</i> , 1998, 18, 358-358.	3.9	13
623	Pharmacological opportunities and pitfalls in the therapy of migraine. <i>Current Opinion in Neurology</i> , 2001, 14, 341-345.	3.6	13
624	New directions in migraine research. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 368-373.	1.5	13
625	Paroxysmal raised intracranial pressure associated with spinal meningeal cysts. <i>Journal of Neurology</i> , 2005, 252, 273-282.	3.6	13
626	Treatment of miscellaneous idiopathic headache disorders (group 4 of the IHS classification) - Report of an EFNS task force. <i>European Journal of Neurology</i> , 2011, 18, 803-e57.	3.3	13
627	Guidance for the management of headache in sport on behalf of The Royal College of General Practitioners and The British Association for the Study of Headache. <i>Cephalalgia</i> , 2011, 31, 106-111.	3.9	13
628	Primary Sex Headache in Adolescents. <i>Pediatrics</i> , 2012, 130, e439-e441.	2.1	13
629	Functional Imaging in Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2013, 17, 333.	2.9	13
630	Sphenopalatine (pterygopalatine) ganglion stimulation and cluster headache: New hope for ye who enter here. <i>Cephalalgia</i> , 2013, 33, 813-815.	3.9	13

#	ARTICLE	IF	CITATIONS
631	The utility of radioisotope cisternography in low CSF/volume syndromes compared to myelography. <i>Cephalalgia</i> , 2016, 36, 1291-1295.	3.9	13
632	Biochemical Modulation and Pathophysiology of Migraine. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 470-479.	0.8	13
633	Visual snow syndrome: is it normal or a disorder and what to do with patients?. <i>European Journal of Neurology</i> , 2020, 27, 2393-2395.	3.3	13
634	Visual snow syndrome: a comparison between an Italian and British population. <i>European Journal of Neurology</i> , 2020, 27, 2099-2101.	3.3	13
635	Mechanistic Investigations Support Liver Safety of Ubrogepant. <i>Toxicological Sciences</i> , 2020, 177, 84-93.	3.1	13
636	CGRP pathway monoclonal antibodies for cluster headache. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 947-953.	3.1	13
637	Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2 <sup>nd</sup> preventives were not useful: results from the LIBERTY study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 466-472.	1.9	13
638	Trigeminal autonomic cephalgias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72 Suppl 2, ii19-ii26.	1.9	13
639	Electrical stimulation of the fastigial nucleus increases total cerebral blood flow in the monkey. <i>Neuroscience Letters</i> , 1989, 107, 141-144.	2.1	12
640	Bench to bedside. <i>Current Opinion in Neurology</i> , 1997, 10, 215-220.	3.6	12
641	Is a central action of acute antimigraine drugs essential?. <i>Cephalalgia</i> , 1997, 17, 10-11.	3.9	12
642	Helospectin-Like Peptides: Immunochemical Localization and Effects on Isolated Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 61-67.	4.3	12
643	Are Triptans with Enhanced Lipophilicity Used for the Acute Treatment of Migraine Associated with an Increased Consulting Rate for Depressive Illness?. <i>Cephalalgia</i> , 2000, 20, 732-737.	3.9	12
644	No relationship between vasoactive intestinal polypeptide expression and headache in pituitary tumours. <i>Acta Neurologica Scandinavica</i> , 2005, 111, 317-322.	2.1	12
645	Cortical modulation of thalamic function during cortical spreading depression- Unraveling a new central mechanism involved in migraine aura". <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	12
646	The enigma of the interconnection of trigeminal pain and cranial autonomic symptoms. <i>Cephalalgia</i> , 2016, 36, 727-729.	3.9	12
647	Exploding head syndrome, snapping of the brain or episodic cranial sensory shock?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1259-1260.	1.9	12
648	Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. <i>Neurology</i> , 2017, 89, 279-283.	1.1	12

#	ARTICLE	IF	CITATIONS
649	Migraine Therapy: Current Approaches and New Horizons. <i>Neurotherapeutics</i> , 2018, 15, 271-273.	4.4	12
650	Proposal for a Migraine Aura Complexity Score. <i>Cephalalgia</i> , 2019, 39, 732-741.	3.9	12
651	Therapeutic targeting of nitroglycerin-mediated trigeminovascular neuronal hypersensitivity predicts clinical outcomes of migraine abortives. <i>Pain</i> , 2021, 162, 1567-1577.	4.2	12
652	Same-Day Bilateral Decubitus CT Myelography for Detecting CSF-Venous Fistulas in Spontaneous Intracranial Hypotension. <i>American Journal of Neuroradiology</i> , 2022, 43, 645-648.	2.4	12
653	An interactive, readily transportable program using a log/logit transformation for the analysis of radioimmunoassay data. <i>Computer Methods and Programs in Biomedicine</i> , 1986, 23, 263-268.	4.7	11
654	Pseudopseudohypoparathyroidism and spinal cord compression.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 929-931.	1.9	11
655	Is migraine a progressive disorder?. <i>Medical Journal of Australia</i> , 2005, 182, 103-104.	1.7	11
656	The Migrainous Brain: What You See Is Not All You Get?. <i>PLoS Medicine</i> , 2006, 3, e404.	8.4	11
657	Cervicogenic headache: a pain in the neck for some neurologists?. <i>Lancet Neurology</i> , The, 2009, 8, 875-877.	10.2	11
658	Paroxysmal sneezing after hypothalamic deep brain stimulation for cluster headache. <i>Cephalalgia</i> , 2012, 32, 641-644.	3.9	11
659	Aprepitant for the management of nausea with inpatient IV dihydroergotamine. <i>Neurology</i> , 2016, 87, 1613-1616.	1.1	11
660	Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic. <i>Journal of Headache and Pain</i> , 2019, 20, 69.	6.0	11
661	Targets for migraine treatment: beyond calcitonin gene-related peptide. <i>Current Opinion in Neurology</i> , 2021, 34, 363-372.	3.6	11
662	Neuronal nitric oxide synthase regulates regional brain perfusion in healthy humans. <i>Cardiovascular Research</i> , 2022, 118, 1321-1329.	3.8	11
663	Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation. <i>Neuropharmacology</i> , 2021, 195, 108375.	4.1	11
664	Migraine as a Cerebral Ionopathy with Impaired Central Sensory Processing. , 2007, , 439-461.		11
665	Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms. <i>Journal of Headache and Pain</i> , 2022, 23, 18.	6.0	11
666	Acetylsalicylic acid inhibits cerebral cortical vasodilatation caused by superior sagittal sinus stimulation in the cat*. <i>European Journal of Neurology</i> , 1994, 1, 141-146.	3.3	10

#	ARTICLE	IF	CITATIONS
667	Nociceptive-specific blink reflex and glyceryl trinitrate infusion in healthy volunteers. <i>European Journal of Neurology</i> , 2003, 10, 295-299.	3.3	10
668	Cluster headache: focus on emerging therapies. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 895-907.	2.8	10
669	Functional neuroimaging of primary headache disorders. <i>Current Pain and Headache Reports</i> , 2005, 9, 141-146.	2.9	10
670	Response to: Migraine and Vertigo: A Marriage of Convenience?. <i>Headache</i> , 2011, 51, 308-309.	3.9	10
671	A trans-cultural comparison of the organisation of care at headache centres world-wide. <i>Cephalalgia</i> , 2011, 31, 316-330.	3.9	10
672	How do we fashion better trials for neurostimulator studies in migraine?. <i>Neurology</i> , 2013, 80, 694-694.	1.1	10
673	Chirp stimulation: H-response short and dynamic. <i>Cephalalgia</i> , 2014, 34, 554-558.	3.9	10
674	Stress and migraine: Something expected, something unexpected. <i>Neurology</i> , 2014, 82, 1388-1389.	1.1	10
675	Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. <i>Neurology</i> , 2016, 87, 2522-2526.	1.1	10
676	Multinational descriptive analysis of the real-world burden of headache using the Migraine Buddy application. <i>European Journal of Neurology</i> , 2021, 28, 4184-4193.	3.3	10
677	Integrating headache trigger management strategies into cognitive-behavioral therapy: A randomized controlled trial.. <i>Health Psychology</i> , 2021, 40, 674-685.	1.6	10
678	Extracerebral Levels of Circulating Vasoactive Peptides during Migraine Headache. <i>Cephalalgia</i> , 1989, 9, 292-293.	3.9	9
679	The oligemic phase of cortical spreading depression is not blocked by tirilazad mesylate (U-74006F). <i>Brain Research</i> , 1992, 588, 140-143.	2.2	9
680	Nitric oxide is not the sole determinant of hypercapnic or metabolically driven vasodilation in the cerebral circulation. <i>Journal of the Autonomic Nervous System</i> , 1994, 49, 67-72.	1.9	9
681	Verapamil and lymphomatoid papulosis in chronic cluster headache. <i>Journal of Neurology</i> , 2004, 251, 473-475.	3.6	9
682	Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 663-665.	1.9	9
683	A Novel Translational Animal Model of Trigeminal Autonomic Cephalalgias. <i>Headache</i> , 2015, 55, 197-203.	3.9	9
684	Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members'™ View in an AIP Mutation-Positive Family. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-15.	1.5	9

#	ARTICLE	IF	CITATIONS
685	Primary cough headache treated with non-invasive vagal nerve stimulation. <i>Neurology</i> , 2020, 95, 593-594.	1.1	9
686	Economic evaluations in migraine: systematic literature review and a novel approach. <i>Journal of Medical Economics</i> , 2020, 23, 864-876.	2.1	9
687	Cluster headache in primary care: unmissable, underdiagnosed and undertreated. <i>British Journal of General Practice</i> , 2006, 56, 486-7.	1.4	9
688	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. <i>Headache</i> , 2022, 62, 453-472.	3.9	9
689	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. <i>European Journal of Neurology</i> , 2022, 29, 2473-2480.	3.3	9
690	Case Report: Transformation of Visual Snow Syndrome From Episodic to Chronic Associated With Acute Cerebellar Infarct. <i>Frontiers in Neurology</i> , 2022, 13, 811490.	2.4	9
691	Triptan medications to treat acute migraine. <i>Lancet</i> , The, 2002, 359, 1152-1153.	13.7	8
692	Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients. <i>European Journal of Neurology</i> , 2006, 13, 1346-1351.	3.3	8
693	Recent Neuroimaging Advances in the Study of Primary Headaches. <i>Current Pain and Headache Reports</i> , 2015, 19, 15.	2.9	8
694	Migraine: a brain state amenable to therapy. <i>Medical Journal of Australia</i> , 2020, 212, 32-39.	1.7	8
695	Candesartan in migraine prevention: results from a retrospective real-world study. <i>Journal of Neurology</i> , 2020, 267, 3243-3247.	3.6	8
696	Types of Headache. , 2005, , 17-24.		8
697	Emerging Treatment Options for Migraine. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 226-235.	0.4	8
698	Serotonin receptors and the acute attack of migraine. <i>Clinical Neuroscience</i> , 1998, 5, 18-23.	0.1	8
699	Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. I. The monkey. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1985, 248, R257-R262.	1.8	7
700	Cocaine abuse simulating the aura of migraine.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 628-628.	1.9	7
701	Hereditary juvenile parkinsonism with pyramidal signs and mental retardation. <i>European Journal of Neurology</i> , 1995, 2, 23-26.	3.3	7
702	Sporadic hemiplegic migraine. <i>Neurology</i> , 2003, 60, 536-537.	1.1	7



#	ARTICLE	IF	CITATIONS
703	Enhancing cognitive-behavioural therapy for recurrent headache: design of a randomised controlled trial. <i>BMC Neurology</i> , 2014, 14, 233.	1.8	7
704	Topiramate for migraine prevention in fertile women: Reproductive counseling is warranted. <i>Cephalalgia</i> , 2014, 34, 1097-1099.	3.9	7
705	Eptinezumab for the preventive treatment of migraine. <i>Pain Management</i> , 2021, 11, 113-121.	1.5	7
706	Extracranial Peptide Release following Stimulation of the Superior Sagittal Sinus in the Cat. <i>Cephalalgia</i> , 1989, 9, 294-295.	3.9	6
707	Zolmitriptan: Differences from Sumatriptan. <i>Current Medical Research and Opinion</i> , 2001, 17, s46-50.	1.9	6
708	Somatostatin infusion withdrawal: a study of patients with migraine, cluster headache and healthy volunteers. <i>Pain</i> , 2003, 102, 235-241.	4.2	6
709	Psychiatric side effects during methysergide treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1037-1038.	1.9	6
710	Squeezing life into botulinum toxin A in migraine: Imploding versus Exploding Pain. <i>Pain</i> , 2006, 125, 206-207.	4.2	6
711	Migraine with cranial autonomic features following surgically induced post-ganglionic sympathetic lesion. <i>Acta Neurologica Scandinavica</i> , 2014, 129, e6-e8.	2.1	6
712	Nociception-specific blink reflex: pharmacology in healthy volunteers. <i>Journal of Headache and Pain</i> , 2015, 16, 87.	6.0	6
713	Putting migraine to sleep: Rexants as a preventive strategy. <i>Cephalalgia</i> , 2015, 35, 377-378.	3.9	6
714	Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.62-e1.	1.9	6
715	1557 Alterations in cerebral blood flow during the postdrome phase of a migraine attack captured with arterial spin labelled (asl) mri. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A9.1-A9.	1.9	6
716	Cluster Headache and Calcitonin Gene-Related Peptide More on Quantum Therapeutics in Headache Medicine. <i>JAMA Neurology</i> , 2018, 75, 1179.	9.0	6
717	Cluster Headache in Kuwait: A Hospital-Based Study. <i>Frontiers in Neurology</i> , 2019, 10, 573.	2.4	6
718	Perceptions, experiences, and understandings of cluster headache among GPs and neurologists: a qualitative study. <i>British Journal of General Practice</i> , 2020, 70, e514-e522.	1.4	6
719	Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study. <i>Cephalalgia</i> , 2021, 41, 197-202.	3.9	6
720	Overview of trigeminal autonomic cephalalgias: Nosologic evolution, diagnosis, and management. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 39.	0.5	6

#	ARTICLE	IF	CITATIONS
721	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE <sup>2</sup> for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	3.9	6
722	Letters to the editor. <i>Muscle and Nerve</i> , 1995, 18, 126-130.	2.2	5
723	Cluster Headache. <i>Practical Neurology</i> , 2001, 1, 42-49.	1.1	5
724	Low CSF Volume (Pressure) Headache. <i>Practical Neurology</i> , 2002, 2, 192-197.	1.1	5
725	Hemicrania continua- building on experience and clinical science. <i>Journal of Headache and Pain</i> , 2014, 15, 9.	6.0	5
726	Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?. <i>Headache</i> , 2018, 58, 295-297.	3.9	5
727	Migraine is common in patients with sarcoidosis. <i>Cephalalgia</i> , 2018, 38, 2079-2082.	3.9	5
728	Co-activation of rhythms during alpha band oscillations as an interictal biomarker of exploding head syndrome. <i>Cephalalgia</i> , 2020, 40, 949-958.	3.9	5
729	Emerging Targets for Migraine Treatment. <i>Neurology India</i> , 2021, 69, 98.	0.4	5
730	Primary neurovascular headache. , 2006, , 851-874.		5
731	Migraine as a Cerebral Ionopathy with Abnormal Central Sensory Processing**Some portions of the pathophysiology have appeared fully referenced [1].. , 2007, , 333-348.		5
732	Understanding migraine in women. <i>Practitioner</i> , 2002, 246, 272-8.	0.3	5
733	Noncholinergic, nonadrenergic cortical vasodilatation elicited by thalamic centromedian-parafascicular complex. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1993, 264, R1150-R1156.	1.8	4
734	Sumatriptan and giant cell arteritis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 660-660.	1.9	4
735	Basic Science: Prejunctional and Presynaptic Trigeminovascular Targets: What Preclinical Evidence Is There?. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2004, 1, 1-6.	0.7	4
736	PATHOPHYSIOLOGY OF MIGRAINE. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2006, 12, 52-66.	0.8	4
737	MUMS the word. Migraine with unilateral motor symptoms: what can you say?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 553-553.	1.9	4
738	Spontaneous intracranial hypotension, hygromata and haematomata. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 442-442.	1.9	4

#	ARTICLE	IF	CITATIONS
739	Calcitonin gene-related peptide receptor antagonists and triptans: A tale of two treatments. <i>Neurology</i> , 2010, 75, 1494-1495.	1.1	4
740	Migraine Misdiagnosed as Idiopathic Intracranial Hypertension. <i>Headache</i> , 2011, 51, 1537-1539.	3.9	4
741	New onset migraine with aura after treatment initiation with ivabradine. <i>Journal of Headache and Pain</i> , 2013, 14, 45.	6.0	4
742	The discovery and development of inhaled therapeutics for migraine. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 591-599.	5.0	4
743	Migraine: beyond pain. <i>Practical Neurology</i> , 2021, 21, 475-480.	1.1	4
744	Evolving options for the treatment of cluster headache. <i>Current Opinion in Neurology</i> , 2020, 33, 323-328.	3.6	4
745	Sumatriptan is not the only analgesic used inappropriately. <i>BMJ: British Medical Journal</i> , 1998, 317, 1016-1016.	2.3	4
746	Inflammation in migraine or not: A critical evaluation of the evidence. <i>Headache</i> , 2021, 61, 1575-1578.	3.9	4
747	The effect of infusion of various peptide antisera on vasodilatation in the cat common carotid vascular territory. <i>Clinical and Experimental Neurology</i> , 1985, 21, 115-21.	0.0	4
748	Subcutaneous sumatriptan and the migraine aura. <i>Neurology</i> , 1996, 46, 286-286.	1.1	3
749	Understanding Migraine Pathophysiology Through Studying the Mechanism of Action of Rizatriptan. <i>Headache</i> , 1999, 39, S2-S8.	3.9	3
750	Evidence for hypothalamic activation in cluster headache. <i>Italian Journal of Neurological Sciences</i> , 1999, 20, S80-S83.	0.1	3
751	Migraine Management: Contrasting Patient Preferences With Current Clinical End Points: Introduction. <i>Headache</i> , 2002, 42, 1-2.	3.9	3
752	Abnormal Blink Reflex Studies in a Patient With Supraorbital Neuralgia. <i>Cephalalgia</i> , 2006, 26, 875-878.	3.9	3
753	Acromegaly. <i>New England Journal of Medicine</i> , 2007, 356, 1274-1276.	27.0	3
754	All that is obvious is not clear: What is the origin of throbbing pain in migraine?. <i>Pain</i> , 2013, 154, 970-971.	4.2	3
755	Comment: How do triptans work in migraine?. <i>Neurology</i> , 2015, 84, 2129-2129.	1.1	3
756	Site of effect of LY2951742 for migraine prophylaxis: Authors' reply. <i>Lancet Neurology</i> , The, 2015, 14, 32-33.	10.2	3

#	ARTICLE	IF	CITATIONS
757	James W. Lance MD. Headache, 2019, 59, 825-827.	3.9	3
758	The need for continued care after sponsor closure – Authors' reply. Lancet Neurology, The, 2020, 19, 205-206.	10.2	3
759	Headache research in 2020: disrupting and improving practice. Lancet Neurology, The, 2021, 20, 7-8.	10.2	3
760	Emerging drugs for the prevention of migraine. Expert Opinion on Emerging Drugs, 2021, 26, 271-280.	2.4	3
761	Paroxysmal hemicrania responding to topiramate. BMJ Case Reports, 2009, 2009, bcr0620092007-bcr0620092007.	0.5	3
762	The Role of Noninvasive Neuromodulation in Migraine Management. European Neurological Review, 2016, 11, 106.	0.5	3
763	Is migraine a progressive disorder? Considering the clinical implications of new research data on migraine and brain lesions. Medical Journal of Australia, 2005, 182, 103-4.	1.7	3
764	Emerging Treatment Options for Migraine. Annals of the Academy of Medicine, Singapore, 2020, 49, 226-235.	0.4	3
765	Vasoactive Peptides and the Carcinoid Syndrome. Annals of Internal Medicine, 1988, 108, 904.	3.9	2
766	MASSIVE BENIGN THYMOMA PRESENTING AS OCULAR MYASTHENIA. Australian and New Zealand Journal of Medicine, 1989, 19, 257-258.	0.5	2
767	MATTERS ARISING. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 94-94.	1.9	2
768	Migraine treatment and mistreatment: <i>primum non nocere</i> . Medical Journal of Australia, 2000, 172, 412-413.	1.7	2
769	Headache. Current Opinion in Neurology, 2002, 15, 285-286.	3.6	2
770	Letters to the Editor. Headache, 2003, 43, 814-823.	3.9	2
771	14 mmHg: a case of raised intracranial pressure?. British Journal of Neurosurgery, 2004, 18, 303-306.	0.8	2
772	Cluster Headache and Other Trigeminal Autonomic Cephalalgias. , 2005, , 195-252.		2
773	Onset of cluster headache triggered by emotional effect: a case report. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1097-1099.	1.9	2
774	Headache. Neurotherapeutics, 2010, 7, 149-152.	4.4	2

#	ARTICLE	IF	CITATIONS
775	Herbalism helps headache. <i>Brain</i> , 2012, 135, 318-319.	7.6	2
776	O011. Patients with "prolonged aura" do not show clinical or demographic differences from the patients with "atypical aura". <i>Journal of Headache and Pain</i> , 2015, 16, A67.	6.0	2
777	Lorcaserin Safety in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2019, 380, 99-100.	27.0	2
778	Recent Advances in the Management of Cluster Headache. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	1.8	2
779	Medically unexplained symptoms: (Letter 2 of 5). <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 368-369.	2.0	2
780	Migraine: Nonvascular/neurally acting drugs as novel treatment strategies. <i>Drugs of the Future</i> , 2006, 31, 969.	0.1	2
781	Premonitory-like Symptomatology in Migraine. <i>European Neurological Review</i> , 2017, 12, 28.	0.5	2
782	Unique Migraine Subtypes, Rare Headache Disorders, and Other Disturbances. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 1032-1040.	0.8	2
783	Migraine and sleep: new connections. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2013, 2013, 15.	0.1	2
784	Dilatation in the carotid vascular territory of the cat in response to activation of cell bodies in the locus coeruleus. <i>Clinical and Experimental Neurology</i> , 1984, 20, 63-72.	0.0	2
785	Bench to bedside: what have we learnt recently about headache?. <i>Current Opinion in Neurology</i> , 1997, 10, 215-20.	3.6	2
786	Mechanisms and management of headache. <i>Journal of the Royal College of Physicians of London</i> , 1999, 33, 228-34.	0.2	2
787	KCl-induced repetitive cortical spreading depression inhibiting trigeminal neuronal firing is mediated by 5-HT <sub>1B/1D</sub> and opioid receptors. <i>Cephalalgia</i> , 2022, 42, 1339-1348.	3.9	2
788	Paroxysmal cerebellar ataxia. <i>Australian and New Zealand Journal of Medicine</i> , 1990, 20, 103-103.	0.5	1
789	Giant cell arteritis and ophthalmoplegia. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 930-930.	0.5	1
790	TRIGEMINAL AUTONOMIC CEPHALALGIAS: CLUSTER HEADACHE AND RELATED CONDITIONS. , 1999, , 773-791.		1
791	Routes of Administration of Acute Migraine Therapy. <i>Headache</i> , 1999, 39, S35-S39.	3.9	1
792	Genetics of common neurological disorders. , 2002, , 14-31.		1

#	ARTICLE	IF	CITATIONS
793	Cluster headache, other trigeminal autonomic syndromes and the short-lived headaches. , 2002, , 927-938.		1
794	Effect of IL-1 $\beta$ microinjection into the posterior hypothalamic area on trigeminal nociception in the rat. Journal of Neural Transmission, 2003, 110, 1349-1358.	2.8	1
795	Postural Headache and Cerebrospinal Fluid Leak: Believing Is Seeing. Headache, 2003, 43, 681-681.	3.9	1
796	Surgical Treatment of Chronic Cluster Headache. Headache, 2003, 43, 1118-1118.	3.9	1
797	The future of headache. Journal of Neurology, 2004, 251, 630-636.	3.6	1
798	New targets in acute migraine treatment. Future Neurology, 2006, 1, 171-177.	0.5	1
799	Headache: a good year for research. Lancet Neurology, The, 2006, 5, 5-6.	10.2	1
800	Prevention and treatment of cluster headache. Progress in Neurology and Psychiatry, 2009, 13, 9-16.	0.9	1
801	Clinical high-risk factors for subarachnoid hemorrhage. Nature Reviews Neurology, 2011, 7, 134-135.	10.1	1
802	Migraine-like Features in Cluster Headache. Headache, 2014, 54, 555-555.	3.9	1
803	Headache in a Patient With Crowned Dens: Report of a New Case. Headache, 2014, 54, 1211-1216.	3.9	1
804	O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study. Journal of Headache and Pain, 2015, 16, A65.	6.0	1
805	O012. Intra-variability of the characteristics of migraine attacks. Journal of Headache and Pain, 2015, 16, A70.	6.0	1
806	Headache. Seminars in Neurology, 2016, 36, 442-448.	1.4	1
807	Author response: Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology, 2017, 88, 2156-2156.	1.1	1
808	Re: Placebo responses in device studies. Cephalalgia, 2018, 38, 1007-1008.	3.9	1
809	Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium. Neurology, 2018, 91, 167-167.	1.1	1
810	Teaching NeuroImages: Greater occipital nerve injection. Neurology, 2019, 92, e746-e747.	1.1	1

#	ARTICLE	IF	CITATIONS
811	Testing rimegepant for migraine—time to revise the trial design? — Authors' reply. <i>Lancet</i> , The, 2020, 395, 1901-1902.	13.7	1
812	Exploding head syndrome (a.k.a. episodic cranial sensory shock) responds to single-pulse transcranial magnetic stimulation. <i>European Journal of Neurology</i> , 2021, 28, 1432-1433.	3.3	1
813	Multidisciplinary headache clinic-impact of a new model for headache care in Dubai. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106845.	1.4	1
814	Vasoactive Peptides in Migraine and Cluster Headache. , 1993, , 415-423.		1
815	Leber's optic atrophy and ðœrhodanese-activity. <i>Medical Journal of Australia</i> , 1988, 149, 110-111.	1.7	1
816	Extrinsic InnervationTransmitters, Receptors, and Functions—The Parasympathetic Nervous System. , 1997, , 63-67.		1
817	Author's reply on Pathophysiology of migraine. <i>Annals of Indian Academy of Neurology</i> , 2013, 16, 456-7.	0.5	1
818	Areas of cerebral blood flow changes on arterial spin labelling with the use of symmetric template during nitroglycerin triggered cluster headache attacks. <i>NeuroImage: Clinical</i> , 2022, 33, 102920.	2.7	1
819	Chronic tension-type headache. <i>Clinical Evidence</i> , 2002, , 1145-52.	0.2	1
820	Dim the Lights: A Narrative Review of Photophobia in Migraine. <i>Touch Reviews in Neurology</i> , 2022, 18, 14.	0.2	1
821	A Subclavian Bruit in the Thoracic Outlet Syndrome. <i>Annals of Internal Medicine</i> , 1989, 110, 323.	3.9	0
822	The Role of Calcitonin Gene-Related Peptide in Neurally Mediated Facial Flushing. <i>Cephalalgia</i> , 1989, 9, 290-291.	3.9	0
823	Reply to Spierings. <i>Headache</i> , 2000, 40, 767-767.	3.9	0
824	Letters to the Editor. <i>Journal of Clinical Neuroscience</i> , 2000, 7, 377.	1.5	0
825	Prostaglandin E2 injected into the posterior hypothalamus has no effect on trigeminal nociception in the rat. <i>Neuroscience Letters</i> , 2003, 350, 85-88.	2.1	0
826	Cerebral Circulation. , 2004, , 144-146.		0
827	Triggers for Trigeminal Activation: Clinical Abstracts and Commentary. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005, 2, 104-107.	0.7	0
828	Cefalea neurovascular primaria. , 2007, , 875-898.		0

#	ARTICLE	IF	CITATIONS
829	MHC Class II Deficiency. , 2009, , 1306-1308.		0
830	Foreword. Cephalgia, 2009, 29, v-vi.	3.9	0
831	POH02 Impact of chronic vs episodic migraine on disability, health-related quality of life and healthcare resource utilisation in the UK. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e51-e51.	1.9	0
832	Response to Dr Elliot Shevelâ€™s comment on the Editorial â€™The trigeminovascular system does not require a peripheral sensory input to be activatedâ€™ migraine is a central disorderâ€™. Cephalgia, 2012, 32, 1082-1083.	3.9	0
833	Authors' reply to Litwin and Malhotra. BMJ, The, 2012, 344, e3551-e3551.	6.0	0
834	Total migraine freedom (TMF) for single pulse transcranial magnetic stimulation (sTMS) versus triptans for the early acute treatment of migraine. Journal of the Neurological Sciences, 2013, 333, e515.	0.6	0
835	The last two years. Cephalgia, 2013, 33, 811-812.	3.9	0
836	Hemicrania continua- Major Shortcomings in the new classification or rigid thinking is death to progress. Journal of Headache and Pain, 2014, 15, 53.	6.0	0
837	CHARACTERISATION OF THE PREMONITORY STAGE OF MIGRAINE IN PAEDIATRIC MIGRAINEURS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.209-e1.	1.9	0
838	PO069â€™...Clinical characterisation of visual snow. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A30.1-A30.	1.9	0
839	PO070â€™...Treatment effect in visual snow. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A30.2-A30.	1.9	0
840	PO068â€™...The similarities between spontaneous and nitroglycerin-triggered premonitory symptoms in migraineurs. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A29.3-A30.	1.9	0
841	PO067â€™...Nitroglycerin triggering as a human migraine model in clinical research. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A29.2-A29.	1.9	0
842	PO066â€™...Alterations in attention, fatigue and alertness associated with the premonitory and postdrome stages of triggered migraine attacks. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A29.1-A29.	1.9	0
843	Marco Polo of Australian neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 627-628.	1.9	0
844	Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study. Neurology, 2019, 92, 587.2-588.	1.1	0
845	O96â€™...Assessment of the efficacy of erenumab during the open-label treatment (13â€™24 weeks) of subjects with episodic migraine who failed 2â€™4 prior preventive treatments: results of the LIBERTY study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A31.1-A31.	1.9	0
846	Future Therapies for Trigeminal Autonomic Cephalalgias: Cluster Headache and Related Conditions. Headache, 2020, , 257-264.	0.4	0



#	ARTICLE	IF	CITATIONS
847	Development of new or worsening headache after cochlear implant activation: A hypothesis-generating pilot study of incidence, timing, and clinical factors. Cephalalgia Reports, 2020, 3, 251581632095182.	0.7	0
848	Editorial: Functional and Structural Brain Alterations in Headache: A Trait or a State?. Frontiers in Neurology, 2020, 11, 859.	2.4	0
849	Managing external cold-stimulus headache with preventive naproxen. Cephalalgia Reports, 2020, 3, 251581632091569.	0.7	0
850	Response to "Do different treatment strategies of galcanezumab have similar effect on migraine?"™. European Journal of Neurology, 2020, 27, e25.	3.3	0
851	Reader Response: Clinical Characterization of Delayed Alcohol-Induced Headache: A Study of 1,108 Participants. Neurology, 2021, 96, 773-773.	1.1	0
852	Non-invasive vagus nerve stimulation for treatment of cluster headache: a retrospective review of prescribing in England. British Journal of Health Care Management, 0, , 1-11.	0.2	0
853	Bench to bedside understanding of migraine pathophysiology. Journal of the Neurological Sciences, 2021, 429, 118000.	0.6	0
854	Cluster Headache and Paroxysmal Hemicrania. , 2003, , 17-22.		0
855	Headache Basic Anatomy and Physiology of the Trigeminovascular System. , 2003, , .		0
856	Neuromodulatory Approaches to the Treatment of Trigeminal Autonomic Cephalalgias (TACs). , 2007, , 45-47.		0
857	Extrinsic Innervation. , 1997, , 67-70.		0
858	Extrinsic Innervation. , 1997, , 63-67.		0
859	Trigeminal autonomic cephalgias I " cluster headache: diagnosis and treatment. , 2018, , 147-163.		0
860	Trigeminal autonomic cephalgias II-(paroxysmal hemicrania and SUNCT) and other short-lasting headache (hypnic headache). , 2018, , 165-177.		0
861	Migraine a Disorder Involving Trigeminal Pathways Modulated by the Brainstem and Diencephalon. , 2020, , 540-549.		0
862	Author response: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study. Neurology, 2020, 95, 707-708.	1.1	0
863	Myasthenia gravis and splenomegaly. Medical Journal of Australia, 1986, 145, 359-359.	1.7	0
864	Newer triptans: emphasis on rizatriptan. Neurology, 2000, 55, S1-2.	1.1	0

#	ARTICLE	IF	CITATIONS
865	A cell atlas for migraine research. Nature, 0, , .	27.8	0